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Summary
The aim of this thesis was to define the interactions o f the androgen receptor 
(AR) with an analog of a non-steroidal plant compound, Compound A (CpdA), as 
well as two synthetic progestins, medroxyprogesterone acetate (MPA) and 
norethindrone acetate (NET-A). The data presented indicates that CpdA has anti- 
androgenic properties, as it represses androgen-induced activation of both specific and 
non-specific androgen-responsive reporter constructs. It was found that CpdA exerts 
these effects by a mechanism other than competition with androgen for binding to the 
ligand-binding domain (LBD) o f the receptor. On the other hand, it is demonstrated 
that both MPA and NET-A compete with androgen for binding to the AR and induce 
partial agonist activity via the receptor. Using mammalian two-hybrid assays it was 
revealed that CpdA, similar to anti-androgenic compounds that are able to compete 
with androgens for binding to the receptor, represses the androgen-induced interaction 
between the NH2- and COOH-terminals o f the AR (N/C-interaction) without 
competing for binding to the LBD. Furthermore, it was shown that CpdA slightly 
represses the androgen-dependent recruitment o f steroid receptor co-activator 1 
(SRC1) to the activation function (AF2) domain o f the AR. When the effects of MPA 
and NET-A on the N/C-interaction were studied, intriguing results were obtained. 
NET-A, as expected, induced this AR agonist-induced interaction. MPA, however, 
repressed this AR agonist-induced interaction, an effect previously associated with 
anti-androgenic activity, despite displaying partial agonist activity in transctivation 
experiments. On the other hand, both MPA and NET-A induced the interaction 
between SRC1 and the AF2 domain. In additional experiments with CpdA, it was 
found that CpdA did not affect the recruitment of SRC1 to the AF1 domain of the 
receptor; neither did it influence the constitutive activity of the NH2-terminal domain.
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The anti-androgenic activities o f CpdA were confirmed by the toxic effect that this 
compound had on the androgen-dependent lymph node carcinoma o f the prostate 
(LNCaP) cell-line as well as its ability to repress the androgen-induced expression of 
the prostate specific antigen (PSA) protein. Taken together, the results presented in 
this thesis, in combination with the knowledge available on AR function, contribute to 
an improved understanding of AR function. Furthermore, the importance o f defining 
the precise mechanism by which individual compounds exert their effects is 
highlighted. In this regard it is demonstrated that two compounds (MPA and NET-A) 
that display partial agonist activity, can exert their effects via different mechanisms at 
the molecular level. Detecting such differences in the molecular mechanisms of action 
could facilitate the improved design o f progestins as well as aid clinicians and their 
patients in selecting the best method of contraception. Lastly, the insights gained into 
the mechanisms of the anti-androgenic action o f CpdA could be useful in therapeutic 
drug design for diseases, such as prostate cancer, that have an androgen-dependent 
etiology.
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Samevatting
Die doel van hierdie tesis was om die interaksies van die androgeen reseptor 
(AR) met ‘n analoog van ‘n nie-steroiediese plant verbinding, Verbinding A (VbgA), 
sowel as met twee sintetiese progestogene, medroksiprogesteroon asetaat (MPA) en 
noretiendroon asetaat (NET-A), te definieer. Die data verskaf dui daarop dat VbgA 
anti-androgeniese eienskappe besit deurdat dit androgeen-gei'nduseerde aktivering van 
beide spesifieke- en nie-spesifieke androgeen-responsiewe rapporteerderkonstrukte 
onderdruk. VbgA veroorsaak hierdie effekte deur ‘n meganisme wat nie kompetisie 
met androgeen vir binding aan die ligand-bindingsdomein (LBD) van die reseptor 
behels nie. In teenstelling hiermee word getoon dat beide MPA en NET-A kompeteer 
met androgeen vir binding aan die AR en gedeeltelike agonistiese aktiwiteit induseer 
via hierdie reseptor. Deur gebruik to maak van ‘n soogdier twee-hibried essai word 
getoon dat VbgA, soos ander anti-androgeniese verbindings wat kompeteer met 
androgeen vir binding aan die reseptor, die androgeen-gei'nduseerde interaksies tussen 
die NH2- en COOH-terminale van die AR (N/C-interaksie) onderdruk, sonder om te 
kompeteer vir binding aan die LBD. Daarby is dit bewys dat VbgA die androgeen- 
afhanklike werwing van steroied reseptor ko-aktiveerde 1 (SRC1) na die aktiverings 
funksie (AF2) domein van die AR gedeeltelik onderdruk. Die studie van die effekte 
van MPA en NET-A op die N/C-interaksie het interessante resultate opgelewer. NET- 
A, soos verwag, het hierdie AR agonis-gei'nduseerde interaksie geinduseer. MPA, aan 
die ander kant, het hierdie AR agonis-gei'nduseerde interaksie onderdruk, ‘n effek wat 
tevore met anti-androgeniese aktiwiteit geassosieer is, al het die transaktiverings- 
eksperimente daarop gedui dat MPA ‘n AR agonis is. Aan die ander kant, het beide 
MPA en NET-A die interaksie tussen SRC1 en die AF2 domein geinduseer. In 
addisionele eksperimente met VbgA is gevind dat VbgA geen effek het op die
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werwing van SRC1 na die AF1 domein van die reseptor nie en ook geen invloed het 
op die konstitutiewe aktiwiteit van die NHh-terminaal domein nie. VbgA se anti- 
androgeniese eienskappe is bevestig deur die toksiese effekte op die androgeen- 
afhanklike limfknoop karsinoom van die prostaat (LNCaP) sellyn sowel as deur sy 
vermoe om die androgen-gei'nduseerde uitdrukking van die prostaat spesifieke 
antigeen (PSA) protei'en te onderdruk. Die resultate aangebied in hierdie tesis, in 
kombinasie met die beskikbare kennis oor AR funksie, dra by tot ‘n verbeterde kennis 
van AR funksionering. Verder word die belang van die defmiering van die 
meganisme waardeur individuiele verbindings hulle effekte veroorsaak, getoon. In 
hierdie verband is getoon dat twee verbindings (MPA en NET-A), wat gedeeltelike 
agonistiese aktiwiteit besit, hulle effekte via verskillende meganismes op die 
molekulere vlak veroorsaak. Deur hierdie verskille in die molekulere meganismes van 
aksie uit te wys, kan beter progestogene ontwikkel word, en verder sal dit vir dokters 
en hul pas'iente help om die beste voorbehoedmiddel te kies. Laastens, die insig wat 
verkry is ten opsigte van die meganismes van anti-androgeniese aktiwiteit van VbgA 
mag nuttig wees in die ontwerp van terapeutiese middels vir die behandeling van 
siektetoestande met androgeen-afhanklikke etiologie (bv. prostaatkanker).
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Format of this thesis
The supervisors of this project decided that the experimental work presented in this 
thesis should be written-up in manuscript format. The thesis is thus composed of:
(i) a literature review on the appropriate background complete with 
references (Chapter /);
(ii) two manuscripts describing, reporting and discussing the experiments 
undertaken by the candidate (Chapters 2 & 3), each of which is 
followed by a discussion of additional results (data not shown in the 
manuscript) and/or comments and suggestions regarding the current 
data; and
(iii) a discussion of the overall results with emphasis on the implications of 
the study and future perspectives (Chapter 4).
The manuscript presented as Chapter 2 has been accepted for publication in 
Molecular and Cellular Endocrinology [In press].
The manuscript comprising Chapter 3 has not yet been submitted for review, as 
experiments are currently being performed that will be included in the final version of 
the manuscript.
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Chapter 1
1
Introduction
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21.1 Steroid receptors
The androgen receptor (AR) is a member of the steroid receptor (SR) family, a 
subfamily of the nuclear receptor superfamily (Evans, 1988). The steroid receptors 
(SRs) also include the estrogen receptor (ER), glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR) and progesterone receptor (PR). The cloning and 
sequencing of the cDNAs of these SRs, and the subsequent comparison of the 
deduced amino acid sequences, indicate the presence of domains that display a high 
degree of homology amongst the members of the SR family. Functional mapping of 
these domains illustrates that there is a high level of similarity between the members 
of the nuclear receptor superfamily, where the arrangement of the different domains is 
essentially the same for all the members. These functional domains are discussed in 
full detail in section 1 .2 .
The SRs are transcription factors, which are activated upon interaction with 
their specific ligands, the steroid hormones. The mechanism by which the SRs 
mediate their biological effects in target cells is comparable and is discussed 
thoroughly in section 1.3.
The AR is activated when bound by one of its specific ligands, namely the 
androgens, and AR action is repressed when the receptor is bound by anti-androgens. 
The molecular mechanisms by which androgens and anti-androgens exert their effects 
contribute to the understanding of AR action, and are explained in sections 1.4 and 
1.5, respectively.
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1.2 The structural and functional domains of the steroid receptors
1.2.1 Domain arrangement and subfamilies
The members of the nuclear receptor superfamily are believed to have evolved 
from an ancestral multi-domain gene, that, through duplication and mutation, resulted 
in the variety of receptors that exist today (O’Malley, 1989; Laudet et al., 1992). The 
basic structure of these receptors involves the following arrangement of domains 
(reviewed in Tsai and O ’Malley, 1994; and Beato et al., 1995) (refer to figure 1). The 
highly conserved and centrally located DNA-binding domain (DBD) follows the 
hypervariable NH2-terminal domain (NTD). The hinge region links the DBD to the 
COOH-terminal (C-terminal) domain. The C-terminal domain is also conserved 
between members of the family and contains the ligand-binding domain (LBD).
The nuclear receptor superfamily can be diviucd into subfamilies based on 
either the homology of their DBDs or the homology of their LBDs. The sequences of 
the NTDs o f the receptors are hypervariable, making it impossible to group the 
receptors based on this region. Three subfamilies are delineated when the receptors 
are classed according to the similarity of their DBDs. Firstly, there is the thyroid 
hormone-/retinoic acid-receptor subfamily. Secondly, the orphan receptor subfamily, 
for which no physiological ligands have been identified. Lastly, the steroid hormone 
receptor family, which in turn is further divided into the GR group (including the GR, 
PR, MR and AR) and the ER group (including the estrogen-related receptor 1 and 2) 
(Laudet et al., 1992). When the superfamily is divided into subfamilies according to 
the conserved region of the LBD, again, three subfamilies emerge with a receptor 
distribution similar to that found when classed according to the DBD.
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Figure 1: A schematic representation of the structural and functional domains of the 
human AR.
The human AR (919 amino acids), and other steroid receptors, is composed of: a variable 
amino terminal domain (NTD), a highly conserved DNA binding domain (DBD), a hinge 
region, and a ligand binding domain (LBD) at the C-terminal. The numbers indicate the 
numbering of the amino acid residues for the human AR.
1.2.2 The amino-terminal domain (NTD)
In comparison to the other domains o f the SRs, the NTD is the domain that 
varies most with regards to both size and sequence (reviewed in Tsai and O ’Malley, 
1994). This domain is involved in the transcriptional activation of target genes, as the 
activation function (AF1) domain is located here. The NTD accomplishes this 
activation by making direct protein-protein contacts with basal and specific 
transcription factors.
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1.2.3 The DNA binding domain (DBD)
The DBD is the most conserved domain of the steroid receptor family. The 
function of this domain is to mediate the interactions of the SRs with the hormone 
response elements (HREs) of their target genes. These interactions are specific and as 
such, are one of the factors contributing to the specificity o f SR functioning.
The DBD of each SR consists of about 70 amino acid residues and is rich in 
the basic residues, arginine and lysine as well as cysteine residues. This domain also 
contains two zinc clusters (refer to figure 2). Each zinc cluster is composed of four 
cysteine residues, in a tetrahedral arrangement, and a zinc ion located in the centre of 
this tetrahedral arrangement (Freedman et al., 1988). Together, the two zinc finger­
like modules are organised in three a-helices (Luisi et al., 1991), and play a role in 
maintaining the structural integrity of the DBD (Freedman et al., 1988; Zilliacus et 
al., 1992).
The first zinc finger, located at the NFL-terminal side of the DBD, is 
responsible for binding to the DNA (Green et al., 1988), and contains the so-called P- 
box. Three amino acid residues of the P-box are essential for recognition of the 
hormone response element (HRE) (refer to Table 1) and thereby responsible for the 
specificity of binding (Umesono and Evans, 1989).
Together with the LBD, the second C-terminally located zinc finger is 
involved in the dimerization of two receptor molecules (Green and Chambon, 1989). 
This zinc-fmger module contains the D-box. The D-box is composed of the amino 
acid residues located between the first and second cysteine residues of this finger, and 
mediates the dimerization contacts.
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Figure 2: The DBD of the GR, characterised by two steroid hormone 
receptor-specific zinc clusters.
Each zinc finger is composed of four cysteines (C) which tetrahedrally co-ordinate a zinc ion. 
The proximal box (P-box) is responsible for specific DNA-recognition. The the distal box (D- 
Box) mediates DBD-dimerization. Capita! letters represent the amino acid sequence, with X  in 
the P-box representing a positively charged amino acid residue. 
(http://www.neurosci.pharm.utoledo.edu/MBC3320/steroids.htm)
Table 1: The steroid receptors, their DBD P-box sequences, and consensus half-sites to 
which they bind.
P-box
sequence
Steroid
receptor Half-site
CGSCKV GR, MR, PR, AR TGTTCT
CEGCKA ER TGACCT
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1.2.4 The hinge region
The hinge region is a flexible region that limes the DBD to the LBD and 
contains the nuclear localisation signal (NLS). This signal is involved in the nuclear 
import of the GR, PR, and AR and functions by being recognised by the nuclear pore 
complex (Picard and Yamamoto, 1987; Guiochon-Mantel et al., 1989; Jenster et al.,
1993). It is composed of two basic amino acid residues, arginine and lysine, followed 
by a ten amino acid residue spacer and then an arginine-lysine stretch (Robbins et al., 
1991).
1.2.5 The ligand binding domain (LBD)
The LBD of the SRs is composed of about 250 amino acid residues. This 
domain has various regions involved in a number of functions. Firstly, the LBD is 
involved in interactions with the heat-shock proteins (Dalman et al., 1989; Cadepond 
et al., 1991). It is also important in the stabilization of homodimerization (Guiochon- 
Mantel et al., 1989; Fawell et al., 1990) as well as Uunsactivation of transcription 
(Hollenberg et al., 1988; Danielian et al., 1992). The LBD is further involved in 
interactions with co-regulators (Moras and Gronemeyer, 1998). The number and 
location of the NLSs vary between the SRs and a second, ligand-dependent NLS may 
be found in the LBD. Lastly and most importantly, the LBD is the region of the 
receptor to which ligand binds (reviewed in Tsai and O’Malley, 1994 and references 
therein). In contrast to other functions that deperd on small stretches of the amino 
acid sequence, binding of ligand requires most of the LBD.
The crystallographic structures of the LBDs of the hERa, hPR. and rAR, 
complexed with their natural ligands have been determined (Brzozowski et al., 1997; 
Tanenbaum et al., 1998; Matias et al., 2000; Sack et al., 2001) and it was found that
7
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8in such cases the ligand is completely buried within the ligand-binding pocket. The 
secondary structural elements o f the LBD include 12 a-helices and 2 P-strands 
arranged in an anti-parallel orientation, creating the hydrophobic ligand binding 
pocket (reviewed in Beato and Klug, 2000). For the AR however, there are only 11 a -  
helices as helix 2 does not exist. In the unliganded state helix 12 protrudes from the 
LBD leaving the entrance o f the ligand pocket open. Upon ligand binding a 
conformational change takes place in this domain. This involves helix 12 folding back 
towards the LBD and essentially closing the entrance to the ligand-binding pocket 
(figure 3). This realignment of helix 12 also generates a new surface(s) through which 
co-activators can interact with the LBD, and thereby mediate the activity o f the 
activation function 2 (AF2) domain located in helix 12.
A B
Steroid  
A  R i n g
Figure 3: A generalised model of the ligand binding domain of the steroid receptors.
The secondary structural elements o f the ligand binding domain, the 12 a-helices (purple) and 2 13- 
sheets (yellow-green) (A) An orthographic view o f  a steroid (green surface contour) approaching the 
ligand binding cavity o f  a steroid receptor (helices 1-11 shown). (B) An orthographic view o f  the 
ligand-binding cavity o f  a steroid receptor (helices 1-12 shown) after helix 12 (H12) has closed the 
cavity. This results in the predominantly lipophilic ligand being surrounded by the hydrophobic interior 
o f  the receptor (http://pps9900.cryst.bbk.ac.uk/projects/taylor/LPT4PPS/Domain.htm).
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91.3 The molecular mechanisms of steroid hormone action
1.3.1 The specificity of steroid hormone/steroid receptor action
When hormones are released into the circulation, they are dispersed 
throughout the organism. One mechanism by which these endocrine messages exert 
specific effects is by interacting specifically with their respective receptors. There is 
little cross-responsiveness between the different SRs and their natural ligands. 
However, the corticosteroid hormones (aldosterone and glucocorticoid hormones) can 
bind to both the MR and the GR (reviewed in Trapp and Holsboer, 1996; Farman and 
Rafestin-Oblin, 2001).
In contrast to this somewhat stnngent ligand-receptor specificity the SRs 
interact far less stringently with HREs. In fact, for a number of years no major 
differences were detected in the ability of the GR group of receptors to recognise 
specific response elements. Recently, however, a group of response elements that are 
specifically recognised by the AR have been identified (discussed in detail in section 
1.4). Thus, specificity of gene regulation by this group of receptors may be achieved 
at a level other than DNA binding. Possible explanations include the idea of receptor 
distribution, as not all of the SRs are present and/or active in all cells and tissues 
(Strale et al., 1989). Although, it is often the case that more than one SR is expressed 
in a cell and in such cases, the relative levels of expression of the different receptors 
may play an important role. Another factor could be differing rates of metabolism for 
the different hormones, thereby removing specific signals by the metabolism of a 
single hormone to an inactive form (Funder et al., 1988). Furthermore, the capacity of 
the receptors to modulate chromatin structure, as well as interactions of the specific
UNTVERSJTEIT STELLENBOSCH
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receptors with other transcription factors (Truss and Beato, 1993), have also been 
shown to be responsible for the steroid specificity of gene regulation.
1.3.2 Subcellular localisation of steroid receptors
It is generally accepted that in the absence of ligand, the SRs are coupled to 
heat-shock proteins and reside in the cytoplasm. Binding of ligand then causes 
dissociation of the heat-shock proteins from the SRs and the subsequent 
homodimerization and translocation to the nucleus (Tsai and O’Malley, 1994; 
Simental et al., 1991).
The subcellular localisation of the SRs is, however, a controversial topic as the 
distribution of the receptors between the cytoplasm and nucleus appears to be the 
result of nuclear-cytoplasmic diffusion and ATP-dependent cytoplasmic-nuclear 
shuttling (Guichon-Mantel et al., 1991). The majority of ER, AR and PR is in the 
nucleus due to the presence of the NLSs. However, the subcellular localisation o f the 
GR and MR is less clear, because ligand-induced nuclear translocation has been 
reported for both receptors (Beato and Klug, 2000).
1.3.3 The heat-shock proteins (hsps)
It is well established that the heat-shock proteins (hsps), that possess a number 
of important ‘house-keeping’ functions, play an important role in SR action. Under 
non-stress conditions the constitutively expressed hsps are thought to function as 
molecular chaperones, mediating the correct self-assembly of other proteins (Ellis and 
Hemmingsen, 1989). Stress either enhances the expression of these hsps or induces 
the expression of other hsps that are better equipped to function under stress 
conditions (Lindquist, 1986; Welch et al., 1983).
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With respect to SR action, the hsps are found in complex with the unliganded 
SR. These complexes contain at least a SR monomer, a dimer of a 90 kDa heat-shock 
protein (hsp90) and the immunophilin p59 (also known as hsp56). Although the exact 
composition of these complexes is unknown, it is known that these proteins are 
mostly associated with the LBD of the receptor (Pratt et al., 1988; Carson-Jurica et 
al., 1989). Ligand binding causes the non-receptor proteins to dissociate from the 
complex. Hsp90 can re-associate with unliganded receptors in an ATP- and Mg2+- 
dependent manner that involves Hsp70 and other chaperones (Smith, 1993; Bohen et 
al., 1995). The rate of association is faster than the rate of dissociation, and as a result 
most of the unliganded receptor is found associated with hsps.
A number of functions have been attributed to the heat-shock proteins that 
bind the SRs (reviewed in Pratt, 1993; Bohen et al., 1995). It is proposed that they are 
involved in the proper folding of the LBD to ensure that high-affmity ligand binding 
is acquired. Furthermore, it is thought that they may play a role in the transport of the 
SRs through the cytosol. Lastly, they could be involved in maintaining the unliganded 
receptors in a transcriptionally inactive state. More recent findings indicate that hsp90 
may be involved in the recycling/reutilization of nuclear GRs, into a form capable of 
productive interactions with hormone, without the obligatory passage of the receptor 
to the cytoplasm (Liu and DeFranco, 1999).
1.3.4 Translocation to the nucleus
Small molecules are capable of entering the nucleus by passive diffusion 
through the nuclear pores. On the other hand, larger molecules, like the SRs, have to 
be actively transported across the nuclear envelope, through the nuclear pore complex 
(Feldherr et al., 1983, 1984). Proteins needing to enter must first be directed towards
11
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the nucleus and this is achieved by a nuclear targeting sequence. A general bipartite 
NLS has been identified that is conserved throughout the SR family (Dingwall and 
Laskey, 1991). The precise mechanism(s) by which the NLS sequences direct proteins 
into the nucleus is not known. One explanation is that these sequences interact 
directly with the nuclear pore complex. Another explanation would be that these 
sequences interact with soluble proteins, which in turn interact with the nuclear pore 
complex. Formation of the SR dimer may also be important, resulting in co­
translocation of the receptors. Ligand-independent receptor translocation also occurs 
and could be dependent on other proteins for co-transportation. An example of such a 
protein would be hsp70, as it contains a NI.S and is found in the nucleus (Koskinen et 
a l, 1991).
Recently, it has been demonstrated that the 69 amino acid DBD of the GR is 
necessary and sufficient for nuclear export. This domain is unrelated to any known 
nuclear export signals. A 15 amino acid sequence between the two zinc binding loops 
of the GR DBD was found to be critical for nuclear export (Black et a l, 2001)
1.3.5 Receptor dimerization and DNA binding
The SRs bind to their FIREs either as homo- and heterodimers. For a number 
of years it was thought that the members of the SR family strictly form homodimers. 
However, in recent years it has been established that the GR and MR can form 
heterodimers with one another, and as a result increase the functional diversity of 
corticosteroid action (reviewed in Trapp and Holsboer, 1996). It is not yet clear 
whether dimerization takes place before DNA binding ^r as a consequence of DNA 
binding. For the PR and ER it has been shown that dimerization takes place before 
DNA binding (De Marzo et a l, 1992; Fawell et a l, 1990), whereas, for the GR and
12
Stellenbosch University http://scholar.sun.ac.za/
AR it has been demonstrated that dimerization may be a consequence of DNA 
binding (Dahlman-Wright et al., 1990; Schoenmakers et al., 2000).
Both receptors in the SR dimer interact with the DNA (figure 4) (Luisi et al., 
1991). For this reason, most HREs consist of two half-sites that are organised either as 
direct repeats or inverted repeats. Direct repeats refer to half-site sequences on the 
same strand, whereas inverted repeats (also known as palindromic sequences) refer to 
half-site sequences on opposite strands. The division of the steroid receptors into the 
GR or the ER group has been based on the response elements that they recognise 
(refer to Table 1). The GR group recognises the glucocorticoid response element 
(GRE) consensus half-site TGTTCT (Truss and Beato, 1993), whereas, the ER group, 
together with most non-steroid receptor members of the superfamily, recognises the 
estrogen response element (ERE) consensus half-site TGACCT. These half-sites are 
all separated by a three-base pair space; that is important for receptor specificity 
(reviewed in De Luca, 1991; Glass et al., 1991).
Receptor dimerization and DNA binding are however, not essential for the 
SRs to control the activity of natural promoters. These actions of the SRs are 
discussed further in section 1.3.7.
1.3.6 Phosphorylation
It is well established that many transcription factors are regulated by their 
phosphorylation status. All of the SRs are known to be such phosphoproteins. A 
number of studies have highlighted the importance of phosphorylation in receptor 
function (reviewed in Weigel, 1996), which can be summarised as follows. Initial 
analyses revealed that phosphorylation can substantially modify both DNA binding 
and transcriptional activation by the SRs. Unliganded SRs that are bound by hsps
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have basal levels o f phosphorylation. As a result of ligand binding, these receptors 
exhibit increases in phosphorylation probably by cyclin-dependent kinases and 
mitogen-activated protein (MAP) kinases. Some members of the family possess the 
ability to bind DNA in the absence of ligand, resulting from phosphorylation at sites 
different from those involved in ligand-dependent phosphorylation. These ligand- 
independent phosphorylation sites have frequently been found to be casein kinase II 
or protein kinase A sites.
Figure 4: A steroid receptor homodimer bound to a hormone response element
A stereoscopic view  o f  the glucocorticoid response clement (double helix shown in yellow on the left) 
with a glucocorticoid receptor homodimer {red and blue structures on the right) bound to it 
(http://users.rcn.com/jkirnball.ma. ultranet/BiologyPages/S/StcroidREs.html).
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1.3.7 Transcriptional regulation
1.3.7.1 Activation of transcription by steroid receptors
Steroid hormones acting via their respective SRs can modify the rate of 
transcription of their responsive genes, either positively or negatively. One way in 
which the steroid hormones regulate transcription, is via HREs that may be several 
kilobases from their target promoters. RNA polymerase II (RNA Pol II) mediates 
transcription at these target promoters. Initiation of transcription by RNA Pol II 
involves a complex hierarchy of both protein-protein "md protein-DNA interactions, 
which starts with the regulated and ordered assembly of basal transcription factors 
into a pre-initiation complex at the promoter region (Buratowski, 1994). This process 
is generally thought to involve the stepwise assembly of factors. However, there is 
evidence that suggests that stable, pre-formed basal transcription complexes may also 
exist, which contain RNA Pol II in addition to other general transcription factors 
(Koleske and Young, 1994).
TFIID, a multiprotein complex composed of TATA-binding protein (TBP) and 
the TBP-associating factors (TAFus), appears to be the part of the pre-initiation 
complex that plays a central role in the communication between RNA Pol II and other 
activators, such as the SRs. In this case, the SRs bind to their HREs in the promoter 
region and communicate with the TFIID complex directly or via so-called co­
activators (Tsai and O ’Malley, 1994). The role of general transcription factors in 
mediating basal transcription is well documented 3 nd beyond the scope of this thesis 
(for a thorough review refer to Zawel and Reinberg, 1995). Not so well characterised 
is the sequence of events by which the activated, DNA-bound SR achieves
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transcriptional regulation. In this regard the interactions of the SRs with general 
transcription factors as well as co-regulator proteins is of importance.
1.3.7.1.1 Interactions o f  the steroid receptors with the pre-initiation complex
Direct protein-protein interactions between receptors and general transcription 
factors such as TBP and several TAFns have been ref^rted. For example, by using 
protein-protein interaction assays such as the yeast two-hybrid screen and in vitro 
binding assays with recombinant proteins, it has been shown that a region of the TBP 
associates with the AF-2 domain of RXR (Schulman et al., 1995). Furthermore, it has 
been demonstrated that both the AF-1 and AF-2 domains of the ER bind TBP in vitro 
(Sadovsky et al., 1995). Similarly an interaction between PR and the TAFullO 
subunit o f TFIID has been reported (Schwerk et al., 1995). Not only have the nuclear 
receptors been shown to interact with subunits of the TFIID multiprotein complex, but 
also with other general transcription factors. One such example would be the 
interaction between the AR and TFIIF (McEwan and Gustafsson, 1997).
All of these interactions may modulate a DNA-bound ternary complex o f SR, 
the TFIID complex and other general transcription factors, suggesting that these 
interactions contribute to the assembly of final transcriptional complexes at their 
target promoters.
1.3.7.1.2 The recruitment o f  co-regulators
Recently it has become clear that the nuclear receptors recruit a host of co­
regulators that have two functions (reviewed in McKenna et al., 1999; Glass and 
Rosenfeld, 2000). Firstly, these co-regulators can create an enviroment at the 
promoter that either activates (co-activator) or represses (co-repressor) transcription,
16
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depending on the activation-state of the receptor. Secondly, these co-regulators can 
communicate with the general transcription factors and RNA Pol II. Ultimately, it is 
suggested that the SRs, in association with their co-regulators, achieve transcriptional 
regulation at hormone-regulated promoters by influencing the rate at which the pre­
initiation complex assembles at the promoter. To date a plethora of such nuclear 
receptor-interacting proteins have been identified. To discuss these co-regulator 
proteins in detail is beyond the scope of this thesis.
Briefly, the co-activator proteins can be divided into five groups. The first 
group consists of the ER-associated proteins (ERAPs) and receptor-interacting 
proteins (RIPs). The second group involves the SRC family, which is a very large 
group of 160-kDa proteins, also referred to as the pi 60 nuclear receptor co-activators. 
There is also a group of selective co-activators, including the androgen receptor 
activator proteins (ARAs) (for a thorough review refer to Heinlein and Chang, 2002). 
The co-integrators, such as the CREB-binding protein complex (CBP/p300), that have 
been shown to interact with the nuclear receptors and other co-activators, are another 
group. The last group includes all the other co-activators that do not fall into related 
families and include the TR-associated proteins and vitamin D receptor interacting 
proteins (TRAPs/DRIPs), positive co-factors as well as TAFns. These co-activator 
proteins have been shown to interact with the nuclear receptors (including the SRs) 
and enhance transcription.
For nuclear receptor co-repressors on the other hand, there is limited data 
supporting direct contacts between these proteins and the nuclear receptors. The co­
repressors are involved in active repression by the thyroid hormone-/retinoic acid- 
receptor subfamily. In this case, the co-repressors are recruited to the unliganded 
receptors to create an enviroment that is incompatible with proper assembly of the
17
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pre-initiation complex. A few co-represscr proteins have been identified that interact 
with this nuclear receptor subfamily. One such protein is NCoR (nuclear receptor co­
repressor), also referred to as RIP-13, that associates with unliganded TR, RAR and 
RXR (Horlein et al., 1995; Seol et al., 1996). Another co-repressor is SMRT 
(silencing mediator for retinoid and thyroid hormone receptor), also identified as 
TRAC2 (T3 receptor-associating cofactor 2), which has been shown to interact with 
RXR, RAR and TR (Chen and Evans, 1995; Sande an... Privalsky, 1996). Recently, it 
has been demonstrated that SMRT can binci to the NH2-terminus of the hAR when 
treated with the anti-androgen cyproterone acetate (Dotzlaw et al., 2002). 
Furthermore, direct interactions between the unliganded AR and NcoR have been 
demonstrated (Cheng et al., 2002).
1.3.7.2 Repression of transcription by steroid receptors
In addition to the members of thyroid hormone-/retinoic acid-receptor 
subfamily, the SRs are also involved in repression of gene expression. A number of 
mechanisms have been proposed for transcriptional repression by the SRs. One such 
mechanism would be via negative HREs. An example would be the negative 
glucocorticoid response element (nGRE) found in the proopiomelanocortin (POMC) 
gene. This nGRE shows sequence homology to the regular GRE, but instead of 
binding as a dimer, the GR binds as a trimer and negatively regulates expression of 
the gene (Drouin et al., 1993). It is, howevei, still unclear whether these elements are 
actually negative or merely overlap with the sites to which other stimulatory proteins 
bind (Drouin et al., 1993).
Another mechanism of transcriptional repression by the SRs involves the 
tethering of the SR to other transcription factors. Genes under positive control o f the
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transcription factors, activator protein 1 (AP-1) or nuclear factor kB (NF-kB) provide 
us with such examples. Mutual antagonism has been reported between the SRs and 
the components of AP-1, the Fos and Jun proteins (reviewed in Herrlich and Ponta,
1994). The regulatory interactions between the AP-1 complex and the SRs are likely 
to involve direct protein-protein interaction between the two proteins. Similarly, it is 
known that NF-kB can be antagonized by the ER (Ray et al., 1994), GR (Ray and 
Prefontaine, 1994), PR (Kalkhoven et al., 1996) and AR (Palvimo et al., 1996). This 
antagonism involves direct protein-protein interactions between the SRs and NF-kB. 
Tethering is not, however, limited to the repressive functions of the SRs. In this 
regard it has been shown that the GR can directly interact with signal transducer and 
activator of transcription 5 (STAT5) and thereby act as a transcriptional co-activator 
for STAT5 and enhance STAT5-dependent transcription (Stocklin et al., 1996).
1.3.8 Chromatin remodelling in the control of transcription by the steroid 
receptors
Chromatin is composed of DNA wrapped around the core histones in the 
nucleosome. This arrangement creates severe steric impediments for transcription 
factors that need to gain access to specific recognition sequences. Nuclear receptor, 
co-activator and co-repressor proteins all play a role in remodelling the chromatin and 
thereby control transcription (reviewed in Collingwood et al., 1999). The role that 
these proteins play can be summarised as follows.
SRs such as the GR are capable of recognising and binding to response 
elements within the nucleosome. This is the first step towards the re-arrangement of 
histone-DNA contacts concomitant with the assembly of a functional transcription 
complex. As described above, the SRs recruit co-activator proteins in a ligand-
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dependent manner. By binding to the SRs, these co-activators are brought into contact 
with the chromatin. Co-activators possess the ability to modify the chromatin 
environment by alleviating the repressive effects of histone-DNA contacts, thereby 
indirectly facilitating transcription. They do so by mechanisms including histone 
acetylation and contacts with the basal transcriptional machinery. On the other hand, 
the recruitment of co-repressor proteins to the nuclear receptors, either in the absence 
of ligand or in the presence of receptor antagonists, results in the stabilization of 
chromatin. This mechanism involves the targeting of histone deacetylases. Taken 
together, the nuclear receptors, together with the co-regulator proteins, control gene 
expression by reversibly modifying chromatin structure.
1.3.9 Rapid, non-genomic actions of steroids
Steroids are generally assumed to be involved in the slow regulation of 
cellular processes, at the genomic level. However, rapid biological responses to 
injected steroids were described as early as 60 years ago and recently, it has been 
demonstrated that steroids may modulate cellular activity at a non-genomic level 
(reviewed in Zinder and Dar, 1999; Sutter-Dub, 2002). Steroids have been implicated 
in causing specific plasma membrane effects, as well as co-ordinative effects on both 
membrane and intracellular receptors. Rapid cellular responses to steroids involve 
plasma membrane binding, changes in membrane electrical activity, G and Ras 
proteins, cAMP, cGMP, diacylglycerol, phosphodiesterases, and an array of kinases. 
With respect to membrane receptors, it has been found that for vitamin D and 
estrogens, both cell surface and nuclear receptors may co-exist in target cells. As a 
result of ligand binding, these receptors can then genei'3te both rapid and long lasting 
responses (reviewed in Nemere and Farach-Carson, 1998). Furthermore, it has been
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suggested that the epidermal growth factor (EGF) receptor may be involved in rapid 
aldosterone signalling in MDCK cells (Gekle et al., 2002). Lastly, steroids can be 
integrated in the intracellular signalling network by cross-talk of the SRs with other 
signal transduction pathways (reviewed in Beato and Klug, 2000). Therefore, steroids 
can influence the response to other extracellular signals that are transmitted via 
membrane receptors and activation of protein kinase cascades. Recently, steroid 
stimulation of the Src/Ras/Erk signaling pathway has received much attention 
(reviewed in Migliaccio et al., 2002). Stimulation of the pathway, or its individual 
members, has been observed in different cell-types. The cellular context and 
intracellular localisation of the receptors play a role in determining the biological 
effect brought about by the hormonal stimulation. It has also been shown that the 
steroid receptors directly interact with Src.
1.4 The molecular mechanisms of androgen action
A brief description of the molecular mechanisms of AR action will follow, but 
for a thorough review on the molecular biology of the AR, refer to Gelmann, 2002. 
The AR mediates the physiological effects of the androgen testosterone (T) and its 
metabolite 5a-dihydrotestosterone (DHT) Testosterone is produced and secreted by 
the Leydig cells in the testis and is converted to DHT by the enzyme 5a-reductase, 
either intratesticularly or peripherally. Androgens have a number of important 
functions throughout the body. These include the roles they play in the development 
of the genital tract of the male foetus, the full development and functional 
maintenance of the internal sex organs, as well as the development o f the external sex
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organs and secondary sex traits at puberty. Disruption of AR action can thus result in 
clinical phenotypes ranging from mild, to complete androgen insensitivity syndromes. 
Furthermore, such disruptions are also involved in the development of prostate cancer 
(Quigley et al., 1995).
In the absence of ligand, the AR is coupled to heat-shock proteins and/or co­
repressors and resides in the cytoplasm (Tsai and O’Malley, 1994; Simental et al., 
1991). In its unliganded state the AR is rapidly degraded. This degradation is slowed 
as a result of high affinity androgen binding (Zhou et al., 1995). Binding of androgen 
causes the heat-shock proteins to dissociate from the AR, activates the bipartite 
nuclear localisation signal (Zhou et al., 1994), and results in receptor dimerization and 
DNA binding (Wong et al., 1993).
In addition to binding to the consensus HREs, the activated AR can also bind 
to more specific, complex response elements. This additional group of response 
elements, identified in three androgen-selective enhancers, is exclusively recognised 
by the AR. The recognition and binding of the AR to these specific elements, 
comprising direct repeats of the 5’-TGTTCT-3’-like sequences, is a determinant of 
AR-specificity (Claessens et al., 2001). It has been demonstrated that it is the second 
zinc finger and part of the hinge region of the AR DBD, as opposed to the first zinc 
finger, that is involved in the recognition of these androgen response elements 
(Schoenmakers et al., 1999). In fact, three AR-specific amino acids in the second zinc 
finger were implicated in studies using the probasin enhancer. All of these amino 
acids are located at the surface of the DBD and pointing away from the DNA. It has 
therefore been suggested that it is not a matter of sequence specificity, but rather an
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alternative dimerization mechanism that explains the specificity of the AR for the 
probasin androgen response element (ARE) (Schoenmakers et al., 2000). This 
alternative mechanism would involve a head-to-tail dimerization of the DNA-bound 
AR-DBDs. Evidence for such anti-parallel AR dimers has also been presented by 
Langley et al., 1995. In studies using synthetic direct repeats and mutant derivatives 
of the 5’-TGTTCT-3’ sequence, it was further demonstrated that the AR and not the 
GR can bind the direct repeat efficiently (Schoenmakers et al., 2000). The ability of 
the AR to bind to elements, resembling direct repeats of the 5’-TGTTCT-3’ sequence, 
of a number of known androgen-selective enhancers lus been shown and is reviewed 
in Claessens et al., 2001.
Another feature of the AR is the ligand-dependent interaction that occurs 
between the NTD and the C-terminal domain (referred to as the N/C-interaction) 
(Langley et al., 1995; Doesburg et al., 1997). A functional ligand-dependent 
association of these domains has also been described for the estrogen receptor (Kraus 
et al., 1995) and progesterone receptor (Tetei et al., 199S). The N/C-interaction o f the 
AR was found to be essential for optimal AR function (Ikonen et al., 1997). The AF2 
domain in the LBD was identified as the region of the C-terminal that is involved in 
mediating this interdomain communication (Berrevoets et al., 1998; He et al., 1999). 
Furthermore, two regions in the NTD have been identified that are involved in this 
functional interaction. The first is located near the NH2-tenninus between amino acid 
residues 3 and 36, and the second is located between residues 370 and 494 
(Berrevoets et al., 1998). More specifically, these regions each contain an LXXLL- 
like motif, where L is leucine and X  is any amino acid. The first region contains a 
FXXLF motif (sequence 2 ,FQNLF27) whereas the second region contains a WXYLF
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motif (sequence 433WHTLF437). The FXXLF motif binds AF2 in the C-terminal of the 
AR, and the WXYLF motif binds to a region of the I BD outside of AF2 (He et al., 
2000). As discussed earlier, binding of hormone to the SRs causes helix 12 of the 
LBD to undergo a conformational change, closing down over the ligand-binding 
pocket. Similarly, the binding of androgen to the AR causes the proper closure of the 
pocket by helix 12. Concomitant with this conformational change is the activation of 
the AF2 domain, or more specifically the formation of a new structural surface that 
can interact with other domains or co-factors. For this reason the N/C-interaction is 
ligand-dependent, in that ligand first needs to bind, thereby inducing the closure of 
helix 12 and exposing the AF2 domain for interaction with regions in the NTD. When 
helix 1 2  closes down over the ligand-binding pocket, it also functions to slow the rate 
at which ligand dissociates from the pocket. The subsequent interaction of the NTD 
with the AF2 domain further stabilizes helix 12 thereby assisting the decrease in the 
rate of androgen dissociation (Kemppainen et al., 1999; He et al., 1999).
The AF2 domain of the AR displays weak transcriptional activity in 
comparison to the AF2 domains of other SRs. It has been demonstrated that the ligand 
binding ability of the LBD is imperative for the functioning of the AF2 domain, and 
that in a yeast system the activity of AF2 is enhanced when the hinge region is 
present. These findings suggest that the hinge region is involved in modulating the 
activity of the LBD, probably by providing an interface for interacting proteins 
(Moilanen et al., 1997). A functional interaction has b^en demonstrated between the 
AF2 domain and the p i 60 nuclear receptor co-activators (Alen et al., 1999). The AF2 
core domain located in helix 12, together with a conserved lysine residue in helix 3, 
were found to be mandatory for this interaction with the p i60 proteins. These co­
24
Stellenbosch University http://scholar.sun.ac.za/
activators include SRCL GRIP1/TIF2, and AIB1/ACTR/TRAM1 (as described earlier 
and reviewed in McKenna et al., 1999; Glass and Rosenfeld, 2000; Xu et al., 1999; 
Leo and Chen, 2000). Similarly to the N/C-interaction, this interaction is ligand- 
dependent, in that ligand has to bind to the LBD inducing the closure of the ligand- 
binding pocket by helix 12. This realignment of helix 12 in the presence of ligand is 
believed to form a hydrophobic cleft, composed of helices 3, 5, and 12. The pl60  co­
activators can then bind to the hydrophobic cleft via three highly conserved a-helical 
LXXLL  motifs that are centrally located in their nuclear receptor interacting regions 
(Heery et al., 1997; Voegel et al., 1998).
For the wild-type AR it has been shown that almost the entire NTD is 
necessary for full transcriptional activity. The NFL-terminal AF1 domain has been 
found to be the major activating region of the AR in both mammalian and yeast cells 
(Moilanen et al., 1997). The size and location of the active AF1 domain in the NTD is 
variable, in that it is dependent on the promoter context and the absence or presence 
of the LBD (Jenster et al., 1995). Similarly to the AF2 domain, the AF1 domain of the 
AR interacts functionally with the p i 60 co-activators ' Alen et al., 1999). This is a 
ligand-independent interaction and involves a direct interaction between the AF1 
domain and a glutamine-rich region of the co-activator protein, which is conserved 
amongst the pi 60 co-activator family (Bevan et al., 1999).
The region of the AF2 domain that interacts with the NTD during the N/C- 
interaction and the region of the AF2 domain that interacts with the LXXLL motifs of 
the p i 60 co-activators, overlap (Thompson et al., 2001). This, together with the 
ability o f the p i60 co-activators to interact with both the NTD and the LBD of the
25
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AR, suggests that these co-activator proteins may play a role in bridging the N/C- 
interaction.
Taken together, these mechanisms of AR action provide, in part, an 
explanation for the specificity of the androgen response. Firstly, the AR is able to bind 
to response elements composed of direct repeat aequ. nces, to which other SRs are 
unable to bind. Secondly, binding of Lndrogen to the LBD of the AR induces 
conformational changes in this domain that result in the subsequent N/C-interaction. 
This interaction prolongs the occupation of receptor with low concentrations of 
androgen, a requirement for AR stabilization and function.
1.5 The molecular mechanisms of anti-androgen action
Anti-androgens (or AR antagonists) are compounds that prevent androgens 
from exerting their biological effects. Such compounds are used extensively for the 
treatment of androgen-based dysfunctions. Based on their structure, the anti­
androgens can be divided into two groups, namely the steroidal (e.g. cyproterone 
acetate) and non-steroidal anti-androgens (e.g. hydroxyflutamide).
When considering the various steps involved in SR action, it is apparent that 
there are a number of potential targets for antagonist action. The antagonists compete 
with the agonists for binding to the LBD of the SR and impair the complete 
conversion of the receptor to a transcriptionally active form. Possible target steps 
where such antagonists may exert their action include the dissociation of the hsps
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(Segnitz and Gehring, 1990) as well as the translocation of the receptor to the nucleus. 
Furthermore, dimerization of the SRs (Fawell et al., 1990; Klein-Hitpass et al., 1991) 
and binding of the SR dimer to the DNA response elements (Berry et al., 1990) have 
also been implicated as target steps in antagonist action. Lastly, interactions of the 
DNA-bound SRs with transcription factors (Berry et al., 1990; Klein-Hitpass et al., 
1991) are also potential steps where antagonists may exert their action.
With regards to antagonists that impair the dissociation of non-receptor 
proteins (i.e. hsps) from the inactive receptor-complex, studies using the LNCaP 
(lymph node carcinoma of the prostate) cell-line (Veldscholte et al., 1992b) 
demonstrate this mechanism of anti-androgen action. Here it was shown that 
compounds that act as androgen agonists in this system, result in the dissociation of 
Hsp90 and p59, whereas in the presence of the antagonist ICI 176.334, these proteins 
do not dissociate from the receptor complex.
The subcellular localisation of antagonist-bound AR appears to be dependent 
on the antagonist used. In a study by Berrevoets et al., 1993 it was found that when 
bound by the AR antagonists, hydroxyflutamide and ICI 176.334, the AR remains in 
the cytoplasm. However, when bound by cyproterone acetate, it was found that some 
of the AR was detected in the nucleus. Taken together, these results indicate that 
certain anti-androgens may impair translocation of the AR to the nucleus.
When considering the DNA-binding capacity of antagonist-bound receptor, 
the antagonists for the PR and ER have been divided into two classes (Klein-Hitpass 
et al., 1991; Green, 1990). Firstly, type I antagonists have been identified that inhibit
27
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receptor binding to DNA, and secondly, type II antagonists have been identified that 
induce high affinity DNA binding but prevent receptor interactions with the 
transcription initiation complex. Certain type II antagonists demonstrate partial 
agonist activity. This has been ascribed to the ligand-independent activation function 
in the NTD, but is also dependent on the promoter and cellular context in which it is 
measured (Berry et al., 1990). For the AR both types of antagonists have been 
identified. Cyproterone acetate, which has shown partial agonist activity in 
transactivation assays (Kemppainen et al., 1992), promotes binding of the AR to 
DNA, whereas hydroxyflutamide inhibits binding of the AR to DNA (Wong et al., 
1993).
To date many attempts have been made to characterise and distinguish AR 
agonists and antagonists by elucidation of their distinct mechanisms of action. Due to 
the broad range of AR agonists and antagonists available, no single feature has been 
illuminated by which these compounds can be categorised. For a number of years AR 
antagonists were characterised by their low affinity for the AR. Compounds that 
exhibited an affinity that was less than 1 0 % of that of the synthetic androgen, 
methyltrienolone (R1881), were considered to be anti-androgens (Kemppainen et al., 
1992; Veldscholte et al., 1992a).
Another feature that was explored is the ability of different SR ligands to 
induce different conformations of the receptor. Electromobility shift assays (EMSAs) 
have shown that agonist- and antagonist-receptor-DNA complexes differ in their 
mobility, suggesting distinct changes in the spatial structure of the receptor as a 
consequence of binding by either agonist or antagonist (Kallio et al., 1994b). Limited
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proteolysis of the PR, ER and GR has led to the hypothesis that antagonist activity can 
be ascribed to the induction of a non-functional conformation at the C-terminus of the 
SRs (reviewed in Tsai and O’Malley, 1994). Limited proteolysis studies with the AR 
have, however, yielded conflicting results. Firstly, Kallio et al., 1994a found an 
unaltered conformation of the LBD, similar to that found in the absence of ligand, for 
the anti-androgen bound receptor. Secondly, Kuil et al., 1994 found that in the 
presence of androgen, limited proteolysis yielded a protected fragment consisting of 
the entire LBD, whereas in the presence of anti-androgen a larger fragment consisting 
of the entire LBD and an extension of the hinge region was observed. Lastly, Zeng et 
al.. 1994 found that regardless of whether agonist or antagonists were used, there was 
no difference in the size of the proteolysis-resistant fragment. None of the studies 
performed with the AR suggest the involvement of the extreme C-terminal region, as 
found for the PR, ER and GR (reviewed in Tsai and O’Malley, 1994), suggesting that 
the mechanisms of anti-androgen action may differ from the mechanisms by which 
other SR antagonists exert their action.
More recently the ability of compounds to induce the ligand-dependent N/C- 
interaction of the AR was investigated as a marker for agonist action (Kemppainen et 
al., 1999). In this study it was demonstrated that androgens induce this interaction and 
that anti-androgens inhibit it. However, it was further demonstrated that inhibition of 
this interaction does not necessarily imply antagonist activity. The synthetic progestin, 
medroxyprogesterone acetate (MPA), which displayed weak agonist activity in 
transactivation studies, not only failed to induce this interaction, but also inhibited the 
DHT-induced N/C-interaction. Prior to this study it had been observed that one 
property that distinguished androgen agonists from antagonists was their ability to
29
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stabilise the AR and thereby protect against degradation (Kemppainen et al., 1992). In 
addition, it has been observed that more potent agonist activity is associated with a 
slow dissociation rate and that this retention of receptor-bound agonist is enhanced by 
the N/C-interaction (Zhou et al., 1995). When the ability of MPA to stabilise the AR 
was determined, it was found that 100 nM MPA was required to achieve stabilization 
similar to that achieved with 1 nM DHT (Kemppainen et al., 1999). Furthermore, this 
study showed that antagonist activity is associated with the inability to induce binding 
of the AR to DNA as well as more rapid ligand dissociation. In Kemppainen et al., 
1999 it is concluded that when distinguishing between agonists and antagonist for the 
AR, a number of features are involved. They propose that AR agonist activity can be 
characterised by a slow dissociation rate of bound ligand, stabilisation of the AR with 
agonist concentrations of less than 10 nM, as well as the induction of the N/C- 
interaction. It is further suggested that AR antagonist activity would be best reflected 
by the inability of a ligand to stabilise the AR against degradation at concentrations of 
500 nM or more.
1.6 Compound A, an analogue of a non-steroidal plant compound
Compound A (CpdA) was developed as a stable analogue of a highly labile 
hydroxyphenyl aziridine precursor (Louw et al., 1997) found in the African shrub, 
Salsola tuberculatiformis Botsch. This synthetic compound is non-steroidal as is 
evident from the chemical name, 2-(4-acetoxyphenyl)-2-chloro-/V-methyl- 
ethylammonium chloride, and structure (figure 5).
30
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Figure 5: The chemical structure of 2-(4-acetoxyphenyl)-2-chloro-N-inethyl-ethylammonium 
chloride (Compound A).
The shrub was used by the Kalahari Bushmen for traditional contraceptive 
purposes (Maritz, 1969). Subsequently, it was found that the shrub also causes 
prolonged gestation in sheep (Basson et al., 1969) as well as contraception in rats 
(Louw et al., 1997). A number of studies have been carried out in an attempt to 
elucidate the mechanism(s) of action underlying these activities of both CpdA and the 
shrub. Initial studies using female Wistar rats revealed that CpdA, like the shrub, 
disrupts the oestrus cycle (Louw et al., 1997), while in in vitro studies CpdA was 
shown to inhibit the action of sheep adrenal cytochrome P450cl 1, the final enzyme 
involved in glucocorticoid biosynthesis, similarly to the active compound isolated 
from the shrub (Louw et al., 1997). Furthermore, in vitro studies also indicate that 
CpdA can bind to ovine and rat corticosteroid-binding globulin (CBG), thereby 
displacing endogenous glucocorticoids and thus increasing free glucocorticoid levels 
(Louw et al., 2000b). This was confirmed in studies with female Wistar rats showing 
that both the shrub and CpdA displace glucocorticoids from CBG (Louw and Swart, 
1999). In addition, this study revealed that there are also significant decreases in 
CBG, luteinizing hormone (LH) and adrenocorticotropic hormone (ACTH) levels 
during treatment. Taken together, the results of these studies suggest that the binding
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of CpdA to CBG and the concomitant increase in the levels of free corticosterone, 
may offer part of the explanation for the contraceptive action of CpdA in female rats.
CpdA has been shown to cyciize to the corresponding aziridine, 
acetoxyphenyl methylaziridine, at a physiological pH (figure 6 ). A study to determine 
whether the biologically active component is the aziridine or the open chain 
precursor, CpdA, revealed that CpdA is the inhibiting agent in the cytochrome 
P450cl 1 system (Louw et al., 1997). This study also showed that CpdA is stabilized 
by CBG in both sheep and rat serum, resulting in slower cyclization to the aziridine 
(Louw et al., 1997). Taken together, these results therefore strongly suggest that it is 
CpdA that exerts the biological actions in these experimental systems.
C om p oun d  A:
2-(4 -acetoxyp h en y l)-2 -ch loro -N -  
m eth yl-eth y lam m on iu m  ch lor id e
?
C om p ou n d  A 's azirid ine:
2 -(4 -a ce to x y p h en y l)-l-
m eth y laz ir id in e
Figure 6: The chem ical structures o f Compound A and the aziridine to which it is 
cyclized.
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The ability of CpdA to interact with glucocorticoid binding proteins such as 
the steroidogenic enzymes (Louw et al., 2000a) and plasma steroid-binding globulins 
(Louw et al., 2000b) has led to the following postulation. It has been suggested that 
CpdA could disrupt the oestrus cycle of rats by interacting with glucocorticoid- 
binding proteins and thereby altering the interactions between the hypothalamus, 
pituitary, adrenals and gonads. Furthermore, recent studies from our laboratory 
indicate that CpdA can affect glucocorticoid receptor-mediated activation of 
transcription (data unpublished), suggesting that CpdA may interact with the GR, 
another glucocorticoid-binding protein. This potential interaction between CpdA and 
the GR, together with the fact there is a high degree of homology between the 
members of the SR family, prompted us to investigate whether CpdA interacts with 
the AR, another member of the SR family. Although CpdA is a non-steroidal 
compound, we were not deterred from pursuing this ir vestigation, since a number of 
non-steroidal compounds have been shown to interact with and exert effects via the 
AR (e.g. the anti-androgen, hydroxyflutamide).
1.7 Contraceptive agents administered by injection
Although the combined oral contraceptive pill is often the automatic choice 
for effective contraception, the long-acting progestogen-only injectable contraceptives 
have some advantages and as a consequence are widely used by women (reviewed in 
Kaunitz, 1998). These advantages include greater efficacy, easier compliance, 
avoidance of estrogenic side-effects, as well as greater privacy. An additional 
advantage is that they are an appropriate choice for postpartum or lactating women
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whose status precludes them from using contraceptive doses of estrogen. Some o f the 
disadvantages include irregular bleeding and a slow return to fertility.
Two progestogen-only injectables are offered as conventional contraceptive 
agents in family planning clinics throughout South Africa. They are, depot 
medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN). Little 
is known of the precise molecular mechanisms via which these contraceptive agents 
exert their effects and side-effects. It has however, been demonstrated that these 
agents bind to and interact with a number o f the steroid receptors. This, together with 
the widespread use of these contraceptive agents, prompted the investigation into the 
mechanism(s) by which these compounds may potentially exert effects via the AR.
1.7.1 M edroxyprogesterone acetate
DMPA has been used in clinical practice for more than 30 years by millions of 
women. However, for many years it was banned as a contraceptive in the United 
States until it obtained approval from the Food and Drug Administration for 
contraceptive use in 1992. Since its approval, DMPA has been, and still is, used by 
several million U.S. women (Kaunitz, 1998). DMPA is an aqueous suspension of 17- 
acetoxy 6 -methyl progestin administered by intramuscular injection of 150 mg every 
three months. Medroxyprogesterone acetate (MPA) (figure 8 ) is detected in the serum 
30 minutes after injection, displays long-term action due to slow release into the 
circulation, and has multiple targets, all factors which make MPA a very effective 
contraceptive (reviewed in Mishell, 1996).
MPA elicits its contraceptive effects by abolishing peak mid-cycle 
gonadotropin (luteinizing hormone, LH and follicle-stimulating hormone, FSH) levels
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and as a consequence inhibiting follicular maturation and preventing ovulation 
(reviewed by Mishell, 1996 and Kaunitz, 1998). Although inhibition of ovulation is 
the major effect, two other mechanisms of action are also involved. These include the 
thinning of the endometrium, rendering it unfit to support a blastocyst, and keeping 
the cervical mucous thick and viscous, preventing sperm from reaching the oviduct.
MPA was synthesized as a true progestin, meaning that MPA is a 21-carbon 
series steroid (refer to figure 7 for carbon numbering system), consisting of the 
pregnane nucleus (Darney et al., 1995). Almost all other contraceptive progestins are 
19-nortestosterone derivatives, and as a result have varying degrees of androgenic 
activity (Mishell, 1996). It has, however, been demonstrated that MPA, in addition to 
having high affinity and agonist activity for the PR. also binds to and is an agonist for 
the GR and the AR (Teulings et al., 1980; Bentel et al., 1999; Kemppainen et al., 
1999; Bojar et al., 1979; Bergink et al., 1983; Feil and Bardin, 1979). DMPA has also 
been shown to induce a number of side-effects, including amenorrhea, weight gain, 
headaches and many more (reviewed in Kaunitz, 1998). It is possible that the 
contraceptive actions and side-effects of MPA could be mediated via any of these 
receptors.
n  zi
3 5 7
4 (1)
Figure 7: The steroid hormone carbon num bering system.
The carbons are numbered 1 to 27, and the rings are labelled A to D. 
(http://www.chem.qmul.ac.uk/iupac/steroid/3S01 ,html#3 S 11)
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Not only is MPA used as a contraceptive, but i! is also used for the treatment 
of dysmenorrhea, menorrhagia, endometriosis, endometrial hyperplasia, ovulatory 
pain, pain associated with ovarian disease, premenstrual dysphoria and 
perimenopausal symptoms (Kaunitz, 1998). Furthermore, MPA is used in cancer 
therapy, at 500-1500 mg orally per day for about 12 weeks (Blossey et al., 1996), and 
in hormone replacement therapy, at 10  mg per day for days 1 0  to 2 1  of the 
theratpeutic month (Brunelli et al., 1996). The actions of MPA in tumour regression 
are brought about partly by interactions with the PR (Blossey et al., 1984), but 
predominantly by interactions with the GR (Bojar et al., 1979) or the AR (Teulings et 
al., 1980).
The doses of MPA administered for cancer and hormone replacement 
therapies are much higher than that used for contraceptive purposes. Women using 
MPA as an injectable contraceptive have serum concentrations of about lng/ml 
(Mishell, 1996), which translates to about 2.6 nM. The ability of MPA to exert AR 
agonist activity (Kemppainen et al., 1999). together with the fact that little research 
has been carried out to define the precise mechanisms by which MPA exerts its 
effects, prompted the initiation of the study to define the in vitro interaction of 
circulating, contraceptive doses of MPA with the AR, the results of which are 
reported in chapter 3.
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Figure 8: The chem ical structures o f natural and synthetic androgens and progestins.
The (A) natural androgen, testosterone (T); (B) synthetic androgen, mibolerone; (C) natural progestin, 
progesterone; (D) synthetic progestin, medroxyprogesterone acetate (MPA)', and (E) synthetic 
progestin, norethindrone acetate (NET-A).
O
II
O - C - C H 3 
=  CH
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1.7.2 Norethindrone enanthate
Similarly to DMPA, NET-EN (often referred to as either norethindrone 
enanthate, norethisterone enantate or nuristerate) has been used as an injectable 
contraceptive for many years. NET-EN is formulated in an oily suspension of benzyl 
benzoate and castor oil and is administered by an intramuscular injection of 2 0 0  mg 
every two months (reviewed in Stanczyk and Roy, 1990). After administration, NET- 
EN is slowly hydrolysed by blood esterases to the parent compound, norethindrone 
(NET). NET (structurally related to testosterone) can be further metabolised and 
undergoes extensive reduction of the a , p-unsaturated ketone ring A, forming the 
corresponding dihydro and tetrahydro reduced products. From pharmacokinetic 
studies (Sang et al., 1981) it is evident that post-injection, the serum levels of NET 
and NET-EN increase rapidly, and that at all times the levels of NET exceed those of 
NET-EN. Furthermore, NET is detectable in the circulation for about 74 days after 
injection, whereas NET-EN is only detected for about 43 days. This rapid metabolism 
of NET-EN therefore indicates that it is NET and its metabolites that are the active 
contraceptive compounds. Fotherby et al., 1983, found that over the 60 day interval 
between administrations of NET-EN, the serum levels of NET can range from 0.5 to 
20 ng/ml, which translates to about 1.5 to 59 nM.
Studies in rats demonstrate that NET-EN elicits its contraceptive effects 
primarily through changes in the content of cervical mucous, thereby creating a 
progestogenic phase, which prevents sperm penetration and thus fertilisation 
(Bhowmik and Mukherjea, 1987). Later studies, also in rats, show that NET-EN can 
also block ovulation (Bhowmik and Mukherjea, 1988). This is not surprising as it was 
demonstrated that NET-EN has a long-lasting gonadotropin suppressive effect in 
women (Fotherby et al., 1983).
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NET-EN, like norethindrone acetate (NET-A) (figure 8 ) and ethyndiol 
diacetate, is a 19-nortestosterone progestin. This means that these progestins are 19- 
carbon series steroids and therefore are composed of the androstane nucleus (similar 
to all androgens). When carbon 19 is removed from testosterone, the androgenic 
hormonal effect is converted to a progestogenic one (refer to figure 7 for carbon 
numbering system). However, these “ 19-nor” steroids have been shown to retain 
varying degrees of androgenic activity (Darney, 1995). The ability of NET to bind to 
the PR and the AR. as well as display agonist activity via these receptors, has been 
demonstrated (Deckers et al., 2000). It has also been demonstrated that in human 
mononuclear leukocytes, NET is virtually devoid of binding affinity towards the GR, 
nor does it induce glucocorticoid-like effects on the lymphocyte functions (Kontula et 
al., 1983). Similarly to DMPA, use of NET-EN as a contraceptive agent is associated 
with a number of side-effects. Some of these side-effects are attributed to the 
lingering androgenic effects of the compound (for example lipoprotein synthesis, acne 
and weight gain) (Darney, 1995).
NET-EN is also used for applications other than contraception, including its 
use in hormone replacement therapy. At present, NET-EN is under investigation to be 
used as a male injectable contraceptive in combination with a testosterone ester 
(Kamischke et al., 2002, 2000a, 2000b). In this application, NET-EN functions to 
suppress spermatogenesis by its strong, rapid and sustained suppression of serum FSH 
and testosterone levels.
Taken together, the structural relationship between NET-EN and testosterone 
together with the androgenic properties of NET-EN prompted us to study the 
interaction of circulating, contraceptive doses of NET-EN with the AR at the 
molecular level.
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1.8 Aim and scope of this thesis
The main aim of the studies, described in tne next two chapters, was firstly, to 
establish whether CpdA possesses any androgenic or anti-androgenic activity and 
secondly, to compare the androgenic activity of the two synthetic progestins, 
medroxyprogesterone acetate and norethindrone acetate.
In chapter 2 the potential interaction between CpdA and the AR, a steroid- 
binding protein, is studied. This study was prompted by the fact that CpdA has 
previously been shown to interact with other steroid-binding proteins such as 
steroidogenic enzymes (Louw et al., 2000a) and plasma steroid-binding globulins 
(Louw et al., 2000b). Furthermore, as the AR is a member of the steroid receptor 
family, the specificity of its actions within this family is also addressed in this study. 
The contraceptive activity previously displayed by CpdA (Louw et al., 1997) further 
prompted these investigations with the steroid receptors. This study also attempts to 
define the precise mechanisms by which C pdA exerts its effects via the AR, as such a 
compound could be used as a lead compound in designing drugs that are targeted to 
the AR.
The third chapter describes investigations that directly compare the androgenic 
properties o f MPA and NET-A. To date, little research has been done to compare the 
actions o f these compounds at the molecular level. Hy comparing the androgenic 
activities o f the these compounds the mechanisms by which they exert their effects 
should become clearer, which in turn would provide women and their clinicians with 
more information to facilitate the selection of a method of contraception.
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Both the study with CpdA and the study with the contraceptive compounds 
could shed some light on the general mechanisms of AR action.
In the final chapter the results of these investigations are summarised and 
discussed in the broader context, with emphasis placed on the implications of these 
findings. Lastly, suggestions are made for future investigations.
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Chapter 2
Anti-androgenic properties of Compound A, an analog of a non­
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2.1 Manuscript
Summary
We investigated the interactions between Compound A (CpdA), an analog of a 
hydroxyphenyl aziridine precursor found in an African shrub, and the androgen receptor 
(AR). CpdA represses androgen-induced activation of both specific and non-specific 
androgen DNA response elements. While a similar effect was obtained for the progesterone 
receptor via a non-specific hormone response element, CpdA had no effect on the actions of 
the glucocorticoid and mineralocorticoid receptors. CpdA represses the ligand-dependent 
interaction between the NH2- and COOH-terminal domains of the AR, similarly to well- 
characterized anti-androgens. CpdA also interferes with the interaction of steroid receptor co­
activator 1 (SRC1) with the activation domain AF2 but not with AF1. However, CpdA does 
not compete with androgen for binding to the AR. These results demonstrate that CpdA elicits 
anti-androgenic actions by a mechanism other than competitive binding for the AR.
Introduction
Compound A (CpdA), 2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium 
chloride, is a non-steroidal compound that was developed as a stable analog (figure 1) of a 
highly labile hydroxyphenyl aziridine precursor (Louw et al., 1997) found in the African 
shrub, Salsola tuberculatiformis Botsch. CpdA can interact with steroid-binding proteins such 
as steroidogenic enzymes (Louw et al., 2000a) and plasma steroid-binding globulins (Louw et
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al., 2000b). We were thus prompted to investigate the possible interactions between CpdA 
and other steroid-binding proteins, in particular the steroid receptors.
CH3
+
c h — c h 2—  n h 2 c r
Figure 1: The chem ical structure of 2-(4-acetoxyphenyl)-2-chloro-/V-m ethyl-ethylam m onium  
chloride (Compound A).
The steroid receptors form a subfamily of the nuclear receptor superfamily, a large 
group o f ligand-dependent transcription factors. The steroid receptors include the androgen 
receptor (AR), estrogen receptor, glucocorticoid receptor (GR), mineralocorticoid receptor 
(MR) and progesterone receptor (PR). In general, the inactive steroid receptors reside 
predominantly in the cytosol. The steroid hormones bind to these receptors, which are then 
activated. After activation, the hormone receptor-complex translocates to the cell nucleus 
where it binds to specific DNA sequences, called response elements and subsequently 
regulates gene expression (Evans, 1988; Beato, 1989). There is a high level of similarity 
between the members of the nuclear receptor superfamily, where the arrangement of the 
different domains is essentially the same for all the members. This arrangement involves the 
highly variable NH2-terminal domain (NTD), followed by the highly conserved and centrally 
located DNA-binding domain (DBD) through which the interactions with the response 
elements are mediated. The COOH-terminal (C-terminal) domain that is also conserved 
between members of the family contains the ligand binding domain (LBD), and areas
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involved in stabilization of homodimerisation as well as orchestration of interactions with 
coregulators (Moras and Gronemeyer, 1998). The C-terminal domain is linked to the DBD by 
a region known as the hinge region. A hormone-independeru transcription activation function
1 (AF1) is found within the NTD (Beato et a l, 1995), whereas a hormone-dependent 
activation function 2 (AF2) has been located in the LBD (Danielian et al., 1992; Moilanen et 
a l,  1997).
For the AR, the size and location of the active AF1 domain in the NTD is variable, in 
that it is dependent on the promoter context and the absence or presence of the LBD (Jenster 
et a l, 1995). The transcriptional activity of the AF2 domain of the AR is weak in comparison 
to many of the other steroid receptors (Moilanen et a l, 1997). It has been demonstrated that 
there are functional interactions between these activation domains of the AR and the 160-kDa 
(p i60) nuclear receptor co-activators (Alen et a l,  1999). The closely related p i 60 steroid 
receptor co-activators that include SRC1, GRIP1/TIF2, and AIB1/ACTR/TRAM1 (reviewed 
in: McKenna et a l,  1999; Glass and Rosenfeld, 2000; Xu et a l, 1999; Leo and Chen, 2000), 
have distinct regions that interact with the AF1 and AF2 domains of the AR. Firstly, they 
interact in a ligand-dependent manner with the LBD (AF2) of steroid receptors via three 
highly conserved a-helical LXXLL motifs that are centrally located in their nuclear receptor 
interacting regions (Heery et a l, 1997; Voegel et a l,  1998). Secondly, it has also been 
demonstrated that p i60 co-activators such as steroid receptor co-activator-1 (SRC1) directly 
interact with the NTD of the AR. This interaction is ligand-independent and occurs between 
AF1 of the AR and a glutamine-rich region of the ^o-activator. This region is conserved 
amongst the members of this family of co-activator^ (Bevan et al., 1999). Furthermore, a 
ligand-dependent interaction between the NTD and LBD (N/C-interaction) of the AR has 
been demonstrated (Langley et al., 1995; Doesburg et al., 1997) and found to be essential for
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optimal AR function (Ikonen et al., 1997). Studies to reveal the subdomains involved in this 
interaction indicate that it is AF2 in the LBD that mediates this interdomain communication 
(Berrevoets et al., 1998; He et al., 1999). Two LYXLL-like motifs have also been identified in 
the NTD o f the AR (He et al., 2000), which have been shown to form, in part, the interface 
for the interaction of the NTD with AF2. The ability of the p l60 co-activators to interact with 
both the NTD and LBD indicates that they may play a role in bridging this N/C-interaction.
Prostate cancer is one of the most commonly diagnosed, and leading causes of death 
from cancer in men in westernized society. To date, the most effective therapy available for 
the treatment of prostate cancer is androgen deprivation, which involves either surgical or 
chemical castration (often anti-androgen therapy). This treatment is unable to completely 
eliminate prostate cancer cell populations because, although there is an initial response, this is 
followed by the predictable pattern of relapse, progression to androgen independence and 
eventual death (Sadar et al., 1999 and references therein). The anti-androgenic properties 
displayed by CpdA in our experiments are thus of potential importance.
Materials and methods 
Plasmids
The plasmid pMTV-luc, which contains a luciferase reporter gene driven by the 
mouse mammary tumour vims long terminal repeat, and the plasmid pC3(l)-TATA-luc, 
which contains a luciferase reporter gene downstream of a 204-base pair PvuII/Ss//_ fr a gm e n t 
of the first intron of the C3(l) gene of prostate binding protein are described in Claessens et 
al., 1993. Luciferase reporter constructs driven uy the TK minimal promoter and containing
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the sip enhancer (pSLP-TATA-Luc), or the sc enhancer (pSC-TATA-Luc), or driven by the 
pb proximal promoter (pPB-Luc) are as described in Verrijdt et al., 2000. The plasmid pTAT- 
GRE-Elb-luc, is driven by the E lb  promoter containing two copies o f the rat TAT-GRE (a 
gift from G. Jenster). Plasmids expressing human steroid receptors: pSVARo, pRSV-hGR, 
pRSV-hMR and pSG5-hPR were gifts from A. Brinkmann, R. Evans and H. Stunnenberg. 
The hAR DBD-LBD expression vector, pSG5-hAR(DBD-T BD), as well as the hAR NTD- 
VP16 fusion protein expression vector, pSNATCH-II(hAR-NTD), were previously described 
in Alen et al., 1999. The expression vector for SRC1, pSG5-SRCl, was obtained from M G. 
Parker. The luciferase reporter driven by five Gal4 binding sites, p(Gal4 )5-tata-luc, was a gift 
from G. Folkers (described in Folkers and van der Saag, 1995). The Gal4-DBD and SRC1 
fragment fusion protein expression vector, pGal4DBD-SRC 1(989-1240), was previously 
described in Kalkhoven et al., 1998. The expression vector for the hAR NTD, pSG5-NTD, 
comprises the entire hAR NTD, cloned in frame with three copies of the Flag-peptide, into the 
EcoRI/Bg/II site of the pSG5 vector. The expression vector of residues 1 to 147 of the yeast 
transcription factor GAL4 fused to the hAR NTD (Ml to R538), pAB-Gal4-NTD, was 
described in Alen et al., 1999.
Preparation of test compounds
R 1881, dexamethasone, aldosterone, progesterone and dihydrotestosterone were 
obtained from Sigma. [3H]mibolerone as weli as unlabelled mibolerone were obtained from 
Dupont, NEN. All test compounds (including CpdA) were dissolved in ethanol. These 
compounds were then added to the culturing medium such that the final concentration of 
ethanol did not exceed 0.1%. Control incubations (no test compounds) were performed in the 
presence of only 0 .1  % ethanol.
Stellenbosch University http://scholar.sun.ac.za/
60
Transfections
Monkey kidney CV1 or COS-7 cells (gifts from M.G. Parker) were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% (v/v) fetal calf 
serum (Gibco-BRL Life Technologies), penicillin (100 IU/ml) and streptomycin (100(j.l/ml) in 
a humidified 5% CO2 incubator. For transfection experiments, cells were seeded into 96-well 
tissue culture plates (Nunc, Roskilde, Denmark) at 104 cells per well and grown in phenol red 
free DMEM supplemented with 5% (v/v) dextran-coated charcoal-stripped serum. On day 2, 
cells were transfected with FuGENE6  transfection reagent (Roche Molecular Biochemicals) 
in accordance with the manufacturer’s instructions. The DNA mixture for transfections 
consisted of (per well): 1 0 0  ng of the appropriate luciferase reporter constructs, 1 0  ng of the 
appropriate mammalian steroid receptor expression vector, and 1 0  ng of the cytomegalovirus 
(CMV)-driven (3-galactosidase expression vector (Stratagene). On day 3, media were 
replaced, either with or without the addition of the appropriate hormones or CpdA (synthesis 
of CpdA described in Louw et al., 1997). On day 4, cells were harvested by incubation for 10 
min in 25 |il of 1 X passive lysis buffer (Promega). A 2.5 (il aliquot of cellular extract was 
used for the quantification of luciferase in a Luminoskan Ascent Luminometer with luciferase 
assay reagent (Promega) in accordance with the manufacturer’s instructions. The (3- 
galactosidase activity in a 2.5 p.1 aliquot of extract from each sample was measured with the P- 
galactosidase chemiluminescent reporter gene assay system (Tropix Inc., Bedford, MA, 
U.S.A.). p-Galactosidase readings were used to assess transfection efficiency and normalise 
luciferase readings. The reported values are averages of at least three independent 
experiments, with each condition performed in triplicate.
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Whole Cell Binding Assays
COS-7 cells were maintained as above and seeded in 24-well tissue culture plates 
(Nunc, Roskilde, Denmark) at 5 x 104 cells per well and grown in phenol red free DMEM 
supplemented with dextran-coated charcoal-stripped serum (5%). On day 2, cells were 
transfected (F11GENE6  transfection reagent) with 0.75 pg pSVARo expression vector and 
0.15 pg pCMV-P-galactosidase expression vector. On day 4, the cells were incubated for 90 
min at 37°C with InM [’HJmibolerone in the absence and presence of an increasing 
concentration of unlabelled mibolerone or CpdA. Working on ice, cells were washed three 
times with ice-cold 1 X PBS for 15 min. Cells were then lysed with 200 pi 1 X passive lysis 
buffer (Promega). Lysates were briefly centrifuged to remove cellular debris and total binding 
was determined for 150 pi of cellular extract by scintillation counting. Non-specific binding 
was determined as the counts obtained when cells were incubated with 1 nM [!H]mibolerone 
in the presence of 10 000 X unlabelled mibolerone. Specific bound mibolerone was calculated 
as the difference between total and non-specific binding. p-Galactosidase activity o f 5 pi 
cellular extract was determined as described above. The reported values are averages of three 
independent assays, with each condition performed in triplicate. Data were plotted as the 
percentage [3H]mibolerone specifically bound and normalised by (3-galactosidase activity.
Western Blots
LNCaP cells (obtained from the American Type Culture Collection, Rockville, Md.) 
were maintained in RPMI medium supplemented with 10% (v/v) fetal calf serum, penicillin 
(100 IU/ml) and streptomycin (100 pl/ml). Cells were seeded into 6 -well tissue culture plates 
at 2,5 x 10  ^ cells per well. On day 2, cells were incubated with the indicated test compounds 
at 37°C for 48 hours. On day 4, proteins were extracted by scraping cells off in ice-cold 1 X 
PBS, pelleting cells by centrifugation at 1400 rpm, and dissolving the cellular pellet in 100 pi
61
Stellenbosch University http://scholar.sun.ac.za/
SB-DTT (110 mM SDS, 110 mM DTT, 80 mM Tris pH 6.9 and 10% glycerol). Protein 
concentrations were determined using BCA protein assay reagent (Pierce). An aliquot (3,3 
pg) of the total protein extract was separated on a SDS-10%-polyacrylamide gel and blotted 
onto a nitrocellulose membrane, Hybond ECL (Amersham Life Science). Membranes were 
incubated with the relevant primary rabbit anti-bodies, followed by incubation with goat-anti- 
rabbit (HRP) anti-bodies as secondary anti-body. Expression of the relevant proteins was 
determined using the Western Blot chemiluminescence reagent (NEN, Life science products).
Data manipulation and statistical analysis
The Graph Pad Prism" programme was used for data manipulations, graphical 
representations, and statistical analysis. One-way ANOVA and Dunnet’s multiple 
comparison’s test (post-test) were used for statistical analysis. P-values are represented as 
follows: P < 0.001 by ***; P < 0.01 by ** and P < 0.05 by *. Non-linear regression and one 
site competition were used in whole cell binding assays. For all experiments, the error bars 
represent the SEM of three independent experiments, each performed in triplicate.
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Results
Compound A represses ligand-induced transcriptional activation of both specific and 
non-specific androgen regulatory DNA regions
The ability of CpdA to repress ligand-induced activation of specific and non-specific 
androgen responsive reporter genes was determined in CV1 cells transiently transfected with 
the corresponding reporter gene and a full-length human androgen receptor (hAR) expression 
vector. The transfected cultures were subsequently exposed to the synthetic, non- 
metabolizable androgen, R1881, in the absence and presence of increasing amounts of CpdA.
Two reporters driven by non-specific androgen regulatory regions were used in these 
experiments: pMTVluc and pC3(l)-TATA-luc. It has previously been shown that both of 
these reporter constructs are induced by androgens as weli as glucocorticoids (Verrijdt et al., 
2000; Claessens et al., 1993; Cato et al., 1987; Ham et al., 1988). In figure 2 we demonstrate 
that transcriptional activation of these reporter constructs by InM R1881 is significantly 
repressed by 10 pM CpdA.
In order to test for androgen specificity, we examined the effect of CpdA on ligand- 
induced activation of pSLP-TATA-luc, pSC-TATA-luc and pPB-luc, three reporter constructs 
that are driven by androgen-specific regulatory DNA iegions (Verrijdt et al., 2000). In figure
2 we show that induction of these reporter constructs by 1 nM R1881 is significantly 
repressed by 10 pM CpdA. The results show that repression of androgen-induced activation 
by 10 p.M CpdA is similar for androgen specific and non-specific reporters. At 1 pM, 
however, CpdA only significantly repressed activation of the pSLP-TATA-Luc reporter 
construct.
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Incubations: 1 2 3 4  1 2 3 4  1 2 3 4  1 2 3 4  1 2 3 4
pMTV pC3 pSLP pSC pPB
Figure 2: CpdA (10 jiM) represses R1881-induced (1 nM) activation o f both non-specific (pM TV  
and pC3) and specific (pSLP, pSC and pPB) androgen regulatory regions by ± 70 -  
80% .
CV1 cells were transiently transfected with the respective reporter, the human AR (pSVARo) and 
pCMV-f3-galactosidase expression vectors. Subsequently, the cells were incubated for 24 hrs with: (1) 
no hormone, (2) 1 nM R 1881, (3) 1 nM R1881 plus 1 (.iM CpdA, and (4) 1 nM R1881 plus 10 |iM 
CpdA. Reporters used: (i) pMTV -  a mouse mammary tumour virus promoter; (ii) pC3 -  promoter of 
component C3 o f prostate (steroid-) binding protein; (iii) pSLP -  liver-specific sex-limited protein 
promoter; (iv) pSC -  secretory component promoter; and (v) pPB -  rat probasin promoter. Induction is 
expressed in relative light units (rlu). Results are averages of *>ree independent experiments with each 
condition in triplicate (± SEM).
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The ability of Compound A to repress ligand-induced transcriptional activation is not 
receptor specific
To determine whether or not the repressive action of CpdA was specific for the 
androgen receptor, COS-7 cells were transiently transfected with a GRE-driven reporter 
construct and the relevant human, steroid receptor expression vectors. Again, it is 
demonstrated that 10 |jM CpdA significantly represses R 1 j 81 -induced activation via the AR 
(figure 3A). We also show that CpdA does not repress dexamethasone- or aldosterone- 
induced transcriptional activation via the GR and MR, respectively (figure 3B and 3C). In 
figure 3C there appears to be an increase in reporter activity when the cells were incubated 
with both aldosterone and CpdA. However, statistical analysis of these results indicates that 
the observed increase is not significant. On the other hand, 10 p.M CpdA significantly 
represses progesterone-induced transcriptional activation via the PR, although to a lesser 
extent than via the AR (figure 3D).
Compound A does not compete for ligand binding to the human androgen receptor
In a competitive whole cell binding assay where COS-7 cells were transfected with a 
full-length hAR expression vector, we show that CpdA up to a concentration of 10 p.M is 
unable to fully compete with [’HJmibolerone for binding to the ligand binding domain of the 
hAR (figure 4). Surprisingly, there appears to be a maximal 10-20% decrease in specific 
binding of [3H]mibolerone in the presence of as little as 10 nM CpdA.
To determine whether the CpdA incubation conditions used in the transactivation 
assays resulted in any change in the binding properties of CpdA, the ability of [‘HJmibolerone 
to bind the hAR after incubation of the cells with CpdA for 24 hours was examined by the 
whole cell binding assay. It was found that under these conditions, CpdA (or a potential 
metabolite thereof) still does not compete with [JH]mibolerone for binding to the hAR (data
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Figure 3: CpdA (10 (iM) represses ligand-induced activation of a GRE-driven reporter construct 
via the androgen and progesterone receptors by about 50% and 30%  respectively, but 
has no effect on ligand-induced activation via the glucocorticoid and m ineralocorticoid  
receptors.
COS-7 cells were transiently transfected with the pTAT-GRE-Elb-luc reporter, the relevant full-length 
human steroid receptor and the pCMV-|3-galactosidase expression vectors. Subsequently, the cells were 
exposed to the cognate ligand in the absence and presence of increasing concentrations of CpdA for 24 
hrs. Steroid receptors and ligands used: (A) the human androgen receptor with R1881 as ligand; (B) the 
human glucocorticoid receptor with dexamethasone (Dex) as ligand; (C) the human mineralocorticoid 
receptor with aldosterone (Aldos) as ligand; and (D) the human progesterone receptor with progesterone 
(Prog) as ligand. Induction is expressed in relative light units (rlu). Results are averages o f three 
independent experiments with each condition in triplicate (± SEM).
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not shown). Furthermore, we have found that in a cell-free system, using whole-cell extracts 
from COS-7 cells transfected with a hAR expression vector, CpdA does not compete for 
binding to the LBD of the AR (data not shown). We therefore conclude that CpdA exerts its 
effects by a mechanism that does not involve competitive binding for the LBD of the AR.
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Figure 4: CpdA does not compete with 3[H]mibolerone for binding to the human androgen  
receptor.
COS-7 cells were transiently transfected with the pSVARo and pCMV-p-galactosidase expression 
vectors. Forty-eight hours later they were incubated with 1 nM [’Hjmibolerone in the absence and 
presence of increasing concentrations of either mibolerone (■) or CpdA ( A)  for 90 minutes. 
Competition for binding is illustrated by the percen: of [ HJn.ibolerone specifically bound to the hAR 
(normalised to P-galactosidase expression). Results are averages o f three independent experiments with 
each condition in triplicate (± SEM).
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Compound A interferes with the interaction between the NH 2-terminal domain and 
ligand binding domain of the human androgen receptor
The functional, in vivo, ligand-dependent interaction between the NTD and LBD of 
the AR has previously been demonstrated in both yeast and mammalian cells (Langley et al., 
1995; Doesburg et al., 1997). Here we used a mammalian two-hybrid assay to determine 
whether CpdA interferes with the N/C-interaction of the hAR. In transient transfections, COS- 
7 cells were cotransfected with a GRE-driven reporter construct, an expression vector 
encoding the DBD and LBD of the hAR. as well as an expression vector encoding the NTD of 
the hAR fused to a VP 16 activation domain. In this experiment (figure 5A) we show that 
CpdA on its own is not able to induce transcription and therefore we can conclude that CpdA 
does not induce the N/C-interaction of the hAR. This result would be expected, and is 
consistent with the fact that CpdA does not exhibit androgenic characteristics or compete with 
mibolerone for binding to the hAR. We also show that 0,1 |.iM DHT induces the N/C- 
interaction and that this effect is partially repressed by 1 |.iM CpdA and almost completely 
repressed by 10 (aM CpdA. These results indicate that CpdA prevents the AR from adopting 
the necessary stable conformation that is required to render the receptor transcriptionally 
active, even in the presence of androgen. This anti-androgenic characteristic has been 
previously reported for anti-androgens such as hydroxyflutamide (Langley et al., 1995; 
Kemppainen et al., 1999) and cyproterone acetate (Kemppainen et al., 1999), however, the 
difference being that these anti-androgenic compounds bind competitively to the LBD of the 
AR.
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Figure 5: CpdA interferes with the N/C-interaction o f the hAR, it also interferes slightly but
significantly with the interaction between SRC1 and the AF2 domain of the hAR but 
not with the interaction between SRC1 and the AF1 domain o f the hAR nor the 
transactivating potential o f the hAR NTD.
COS-7 cells were transiently transfected with: (A) the pTAT-GRE-Elb-luc reporter, the pSG5- 
hAR(DBD-LBD), the pSNATCH-II(hAR-NTD) and the pCMV-p-galactosidase expression vectors; (B) 
the pTAT-GRE-Elb-luc reporter, the pSG5-hAR(DBD-LBD), the pSG5-SRCl and the pCMV-p- 
galactosidase expression vectors; (C) the p(Gal4)5-tata-luc reporter, the pGal4DBD-SRCl(989-1240), 
the pSG5-NTD and the pCMV-P-galactosidase expression vectors; and (D) the p(Gal4)5-tata-luc 
reporter, the pAB-Gal4-NTD and the pCMV-P-galactosidase expression vectors. Subsequently, the 
cells were exposed to the indicated test compounds for 24 hrs. Induction is expressed in relative light 
units (rlu). Results are averages of three independent experiments with each condition in triplicate (± 
SEM).
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Compound A impairs SRC1 activation of the AF2 domain, but not the AF1 domain, of 
the androgen receptor
To further elucidate the mechanism by which CpdA represses androgen-induced 
transcriptional activation via the hAR, transient transfections were carried out to determine 
whether or not CpdA interferes with the recruitment .;f the p i60 co-activator, SRC1, to the 
hAR. Firstly, we examined the effect of Cpd,\ on the ligand-dependent recruitment of SRC1 
to the AF2 domain. The ability of the AR LBD to interact with SRC1 in a ligand-dependent 
manner has previously been demonstrated, in a mammalian (Alen et al., 1999) and yeast 
(Bevan et al., 1999) two-hybrid system. In these experiments, the mammalian COS-7 cell-line 
was cotransfected with the GRE-driven reporter construct, the vector expressing the DBD- 
LBD of the hAR, and a SRC1 expression vector. In figure 5B we demonstrate that 10 pM 
CpdA weakly but significantly (P<0.05) interferes with the DHT-induced activation of the 
AF2 domain of the hAR by SRC 1.
Secondly, it has also been shown that SRC1 interacts with the AF1 domain of the AR, 
in both a mammalian (Alen et al., 1999) and yeast (Bevan et al., 1999) system. In both these 
cases, this interaction was demonstrated to be ligand-independent. To investigate the effect of 
CpdA on this interaction, we cotransfected COS-7 cells with a reporter gene driven by five 
Gal4 response elements, the Gal4-DBD and SRC' fusion protein and hAR NTD expression 
vectors. In figure 5C (bars 1 and 2) we show that the interaction between SRC1 and the NTD 
is sufficient to induce a transcriptionally active complex in the absence of ligand, as has been 
previously reported (Bevan et al., 1999). We also show that CpdA, up to a concentration of 10 
|iM, does not interfere with the interaction between SRC1 and the NTD (figure 5C; bars 3-6).
In a similar experiment, COS-7 cells were cotransfected with the Gal4 reporter and a 
Gal4-DBD plus hAR NTD fusion protein expression vector. The recruitment of basal 
transcription machinery to the activation domain of the hAR NTD allows this fusion protein
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to activate transcription at the Gal4 response element (Alen et al., 1999). Incubations with 
varying concentrations of CpdA had no effect on transcription. This result indicates that 
CpdA does not interact with the AF1 activation domain in any way that would interfere with 
the establishment of a transcriptionally competent complex (figure 5D).
Compound A represses basal expression, and inhiuits androgen-induced expression, of 
the prostate specific antigen protein in LNCaP cells
Having shown that CpdA can repress androgen-induced transcriptional activation of 
transiently transfected reporter constructs via the AR, we were prompted to study the effect of 
CpdA on the expression of androgen-dependent, endogenously expressed proteins. For this 
experiment we made use of the androgen-dependent, lymph node carcinoma of the prostate 
(LNCaP) cell-line. We looked at the effect of CpdA on the expression of the prostate specific 
antigen (PSA) protein. PSA, is a clinically important androgen-stimulated gene that is used to 
monitor treatment responses, prognosis and progression of prostate cancer (reviewed by 
Polascik et al., 1999).
In figure 6 A the androgen-dependence of PSA expression is illustrated clearly by the 
effects of the incubation with both R1881 and hydroxyflutamide (which functions as an 
androgen in this cell-line, Veldscholte et al., 1992). We also show that 10 p.M CpdA does not 
induce PSA expression but rather represses even b'isal ?xpr2ssion levels of the protein. When 
the cells are incubated with both R1881 and CpdA, there is an apparent repression of the 
androgen-induced expression of PSA by CpdA. These effects of CpdA on PSA protein 
expression are consistent with the anti-androgenic actions of CpdA observed in the 
transfection experiments. Incubation of the androgen-dependent LNCaP cell-line with CpdA 
appeared to influence the viability of the cells and thus we performed an MTT-based 
proliferation assay. Results from these experiments indicated that both CpdA on its own and
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in the presence of androgen significantly suppressed proliferation of and/or was toxic for this 
cell-line (data not shown), providing additional evidence of the anti-androgenic activity of 
CpdA. On the other hand, when this assay was performed on the COS-7 cell-line we found 
that CpdA had no effect on cell viability (data not shown). Thus it is possible that the anti- 
androgenic effects of CpdA seen in the transfection experiments may be due to the anti- 
androgenic capacity o f CpdA.
B mm mm M— AR
C  m m m m*m CK18
1 2 3 4 5
Figure 6: CpdA (10 |^M) abolishes even basal expression levels o f  PSA (prostate specific antigen) 
protein.
LNCaP cells were incubated with the indicated te .t compounds for 48 hrs and extracts made. Total 
protein (3,3 |ig) was separated on a SDS-IO%-poly?.crylamide gel followed by Western blotting 
(described in Material and Methods). (A) Rabbit-anti-PSA, (B) rabbit-anti-AR and (C) rabbit-anti- 
CK18 primary anti-bodies were used. Test compounds used: (I) no hormone, (2) 1 nM R 1881, (3) 1 
(.iM hydroxyflutamide, (4) 10 CpdA, and (5) I nM R1881 plus IO|.iM CpdA.
Figure 6 B illustrates the effects that these compounds have on AR protein levels. After 
a 24 hour incubation period, R1881 appears to repress the AR protein levels which is 
consistent with reports in the literature (Ye&p et a'l, 1999). Hydroxyflutamide, CpdA and 
CpdA together with R 1881, do not seem to influence AR protein expression levels. Although 
CpdA itself does not regulate AR protein levels, it does appear to inhibit the repressive effect 
of R1881, once again illustrating the anti-androgenic properties of this compound. Figure 6 C
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is a control blot showing the expression of cytokeratin 18 (CK18), a constitutively expressed 
protein.
Discussion
There are a number of diseases that have an androgen-dependent etiology, and/or 
show an undesirable response to circulating androgens. Anti-androgens are used clinically for 
the treatment of such diseases because of their ability to inhibit androgen action. Conventional 
anti-androgenic compounds compete with androgens for occupancy of the AR, without 
eliciting androgen activity. In this investigation we describe a compound that displays anti- 
androgenic potential but does not compete with canonical ligands for occupancy of the AR.
The anti-androgenic action of CpdA was first noted when we found that CpdA was 
able to repress androgen-induced transcriptional activation of enhancer regions specifically 
regulated by androgens (figure 2A). This capability of CpdA to regulate anti-androgenic 
actions at the molecular level was later confirmed by its ability to repress the expression of 
the androgen-dependent PSA protein (figure 6A). We have also found that regardless of 
which AR agonist is used (R1881, mibolerone or DHT), CpdA represses agonist-induced 
transcriptional activation of a GRE-driven reporter via the AR to a similar extent (data not 
shown). Together, these results clearly indicate that CpdA has the ability to interfere with the 
action o f liganded AR. However, the ability of CpdA tv- rep ress ligand-induced transcriptional 
activation via a steroid receptor is not specific for the AR, as CpdA is also capable of 
repressing PR activity to some extent (figure 3D). On the other hand, there is no indication 
that CpdA interferes with activation of transcription via the GR or MR (figure 3B and 3C).
Stellenbosch University http://scholar.sun.ac.za/
74
In a whole cell binding assay, we show that CpdA is unable to compete effectively 
with [3H]mibolerone for binding to the AR (figure 4). Thus, in the presence of CpdA. the 
ligand remains bound to the AR. In light of this unique property, attempts to define the 
mechanism(s) of action of CpdA via the AR led to the finding that CpdA, like anti-androgens 
such as hydroxyflutamide and cyproterone acetate (Kemppainen et al., 1999), is unable to 
induce the interaction between the NfL-terminal and COOH-terminal domains of the AR 
(figure 5A). However, CpdA does inhibit the N/C-interaction that is normally induced when 
the ligand is bound to the receptor, most likley resulting in its anti-androgenic actions. Taken 
together, our results could thus be explained by the following hypothesis. In the presence of 
ligand, CpdA interacts with a region of the AR that inhibits the N/C-interaction, resulting in a 
ligand-receptor complex with an altered, non-optimal conformation that impairs the 
transactivating capacity of the AR.
Experiments were thus carried out to identify the region(s) of the AR with which 
CpdA interacts. Previous studies have shown that it is the two LXYLL-like motifs in the NTD 
(He et al., 2000) and the AF2 domain of the LBD (Berrevoets et al., 1998; He et al., 1999; 
Alen et al, 2000) that are the subdomains involved in the N/C-interaction. The inhibitory 
effect of CpdA on the N/C-interaction is therefore indicative of a potential interaction 
between CpdA and one or more of these subdomains.
Firstly, because the repressive effect of CpdA on the N/C-interaction suggests that 
CpdA may impair the ligand-induced activation of the AF2 domain, we investigated the effect 
of CpdA on a second interaction that relies on the ligand-induced activation of this domain. 
For this reason, we made use of the assay that demonstrates the androgen-induced interaction 
between the p i 60 co-activator, SRC1, and the AF2 domain. If CpdA were to interfere with
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the activation of the AF2 domain, we would expect it to inhibit the interaction between SRC1 
and this domain. Our results show that the ability of CpdA to repress the interaction between 
SRC1 and the AF2 domain (figure 5B) is not of the same magnitude as its ability to repress 
the N/C-interaction and we therefore suggest that it is unlikely that CpdA exerts its anti- 
androgenic activities by a mechanism that involves the absolute inhibition of AF2 domain 
activity. However, although the regions of the AF2 domain involved in the N/C-interaction 
and the interaction with SRC1 overlap, they are not identical. It is therefore possible that 
CpdA may interact with or even modify amino acid residues that are essential for the N/C- 
interaction but not essential for the interaction between SRC1 and the AF2 domain.
Secondly, we investigated the possibility of CpdA interfering with one o f the known 
functions of the NTD of the AR. In these experiments we looked at the effect of CpdA on the 
interaction between SRC1 and the AF1 domain of tne N FD. A direct, ligand-independent 
interaction between SRC1 and the AF1 domain has been established (Bevan et al., 1999). In 
our experiments we found that CpdA had no effect on this interaction (figure 5C) and it is 
therefore unlikely that CpdA interacts with the sites of the AF1 domain through which regions 
of SRC1 interact. This result, however, does not rule out the possibility that CpdA interacts 
with a region(s) of the NTD other than the AF1 domain. For example, it is possible that CpdA 
could interact with the LX\LL-like motifs of the NTD. However, no conclusion on this matter 
can be drawn from our data. To summarise, we show that ii is unlikely that CpdA exerts its 
effects by interactions via the AF2 domain in the LBD or the AF1 domain in the NTD. On the 
other hand, our results do not exclude the possibility that CpdA may interact with other 
regions in the LBD or the NTD.
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Although it is not possible to conclude from our data whether CpdA interacts directly 
or indirectly with the AR, and what the exact nature of this interaction(s) may be, one 
possibility is that CpdA, a hydroxy-phenylaziridine precursor, could be cyclized to the 
aziridine. The aziridines are highly reactive alkylating agents that can react with nucleophilic 
amino acid residues. Thus, incubations with CpdA could result in the modification of 
nucleophilic amino acid residues of the AR that are essential for the N/C-interaction
Taken together, our results indicate that the anti-androgenic actions of CpdA are 
mediated via the AR by a mechanism other than competitive binding for the same site as 
androgen agonists. More research towards elucidating these new mechanism(s), by which 
CpdA and other anti-androgenic compounds elicit their anti-androgenic functions, may be 
helpful in unraveling the molecular mechanisms of action of the AR in normal and 
pathological conditions like prostate cancer.
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2.2 Data not shown / Comments and suggestions
Compound A exerts similar effects in whole cell binding experiments, regardless 
of the length of the incubation time.
In transactivation assays the cells were incubated in the presence of CpdA for 
24 hours, whereas in whole cell binding assays the cells are only incubated with 
CpdA for 1,5 hours. CpdA has been shown ‘u cyclize tr* the corresponding aziridine, 
acetoxyphenyl methylaziridine, at physiological pH. Thus the effects seen in these 
two experiments could be brought about by different active species of CpdA that may 
be active under the specific conditions (e.g. CpdA itself or the aziridine). For this 
reason, a whole cell binding assay was performed where COS-7 cells, transfected with 
a full-length hAR expression vector, were incubated for either 24 or 1,5 hours with 
CpdA, prior to incubation with [ HJmibolerone.
This experiment demonstrates tha., regardless of the length of time that the 
cells are incubated with CpdA (e.g. 24 hours as in the transfection experiments or 1.5 
hours as in the whole cell binding experiments), neither CpdA nor other potential 
species thereof are able to compete with [ H]mibolerone for binding to the hAR 
(figure I). It is therefore accepted that the inability to compete for binding to the AR 
as well as the repression of androgen-induced transcriptional activation are actions of 
the same species of CpdA. In conclusion, CpoA (or th<r active species thereof) does 
not exert its effect by competing for binding to the AR.
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Figure (I): Regardless of the duration of the exposure of the cells to CpdA, androgen is 
still able to bind to the receptor.
COS-7 cells were transiently transfected with the pSVARo and pCMV-p-galactosidase 
expression vectors. Twenty-four hours later cells were exposed to one o f the following  
conditions. Firstly (■), medium was changed and 24 hours later cells were incubated with 1 
nM [3H]mibolerone in the presence o f  increasing concentrations o f unlabclled mibolerone for 
90 minutes (black). Secondly (A ) , medium was changed and 22.5 hours later cells were 
exposed to increasing concentrations o f  CpdA for 90 minutes, followed by an incubation with
1 nM [3H]mibolerone for 90 minutes (blue). Lastly (▼ ), the cells were incubated with 
increasing concentrations o f CpdA for 24 hours, followed by an incubation with 1 nM 
[3H] mibolerone for 90 minutes (red). Competition for binding is illustrated by the percent o f  
[3H]mibolerone specifically bound to the hAR (normalised to P-galactosidase expression). 
Results are averages o f three independent experiments with each condition in triplicate (± 
SEM).
Stellenbosch University http://scholar.sun.ac.za/
Compound A suppresses the proliferation of the androgen-dependent LNCaP 
cell-line, but not that of the COS-7 cell-line.
Upon incubation of LNCaP cells with CpdA (Western blot experiments), it 
was noted that CpdA has an effect on the viability of the cell-line. After an incubation 
period of 48 hours a number of the cells had become rounded and detached from the 
tissue-culture plates. It was thus decided to investigate the potential of CpdA to 
influence the proliferation/viability of these cells under these culturing conditions. 
Here an MTT-based proliferation assay was used. The results obtained indicate that 
CpdA in the absence and presence of androgen can significantly suppress the 
proliferation/viability of these cells. This action of CpdA is consistent with its ability 
to exert anti-androgenic effects. To determine whether the repressive actions of CpdA 
observed in experiments using the COS-7 cell-line were not a result of anti­
proliferative effects or decreased cell viability induced by CpdA, the assay was also 
performed for this cell-line, which lacks endogenous AR. It was found that CpdA did 
not influence the proliferation/viability o f this cell-line, an indication that the anti- 
androgenic effects of CpdA seen in the transfection experiments are attributed to the 
anti-androgenic capacity of CpdA.
It is of importance to note that the MTT assay used in these studies is based on 
the reduction of the tetrazolium salt 3,[4,5-domethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide (MTT) by mitochondrial enzymes associated with 
metabolic activity. Reduction of MTT thus reflects both cell viability and cell 
proliferation. The results obtained in the study with CpdA therefore indicate a 
decrease in the number of viable cells upon treatment with CpdA. To discriminate 
whether this is a result of less proliferation 01 increased toxicity, assays using tritiated
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thymidine incorporation or trypan blue exclusion, respectively, would have to be 
performed.
o e
V1 c
■Q ID
a:
B
DMSO (%) 
R1881 (nM) 
CpdA ((aM)
Figure (II): CpdA (10 ^M) displays anti-proliferative and/or cytotoxic activity in the 
LNCaP cell-line, but not the COS-7 c°ll-Iine.
The (A) lymph node carcinoma o f  the prostate (LNCaP) ~cils, and (B) monkey kidney (COS- 
7) cells were seeded into 24-well and 96-vvcli tissue culture plates at 5 X 105 and 1 X 104 cells 
per well, respectively. Cells were then incubated with the indicated test compounds for 24 hrs. 
Subsequently, MTT (5 mg/ml) was added as one tenth o f  the volume per well and incubated 
for 3 hrs at 37 °C. Medium was aspirated, crystals dissolved in DMSO and OD595 measured. 
Results are averages o f  three independent experiments with each condition in triplicate (±  
SEM).
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Compound A represses, to a similar extent, the transcriptional activation 
induced by different androgens.
Since the whole cell binding assays were performed with mibolerone as 
reference androgen, and other experiments (transfections and Western blots) where 
carried out with either R1881 or DHT as reference androgen, it was difficult to 
directly compare the anti-androgenic effects of CpdA in the various experiments. For 
this reason the ability of CpdA to repress androgen-induced transcriptional activation 
via the full-length AR was directly compared for the different androgens used (DHT, 
R1881 and mibolerone). In figure (III) it is shown that CpdA represses, to a similar 
extent, the DHT-, R1881-, and mibolerone-induced transcription of the GRE-TAT 
reporter construct.
150-
S'
E 1 0 0 -
"roO)i
CO.
o
3  50-  
0 -
R1881 (1 nM)
Mib (1 nM)
DHT (100 nM)
CpdA (1 (.iM)
CpdA (10 |.iM)
Figure (III): The degree to which CpdA represses DHT-, R1881-, and m ibolerone- 
induced transcriptional activation is simih.r,
COS-7 cells were transiently transfected with the pTAT-GRE-Elb-luc reporter, and the 
pSVARo and pCMV-P-galactosidase expression vectors. Subsequently, the cells were 
exposed to DHT, R1881 or mibolerone (at the indicated concentrations) in the absence and 
presence o f  increasing concentrations o f  CpdA for 24 hours. Induction is expressed in relative 
light units (rlu). Results are averages o f  three independent experiments with each condition in 
triplicate (± SEM).
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Additional comments/suggestions
There are a few parameters that could stil! be measured to confirm or validate the data 
presented in this study with CpdA. Firstly, the repressive effects of CpdA on 
transcriptional activation could be compared with those of a known androgen 
antangonist like hydroxyflutamide. Secondly, the repressive effects of CpdA seen on 
the N/C-interaction as well as the recruitment of SRC 1 may reflect an effect of CpdA 
on an event occurring downstream of the actual interaction, as these assays both 
measure the downstream response of these interactions. Therefore, it is suggested that 
GST pull-down assays be performed to determine whether the effect of CpdA on 
these two interactions is in fact direct or indirect.
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3.1 Manuscript
Summary
The aim of the current study was to direcfly compare the relative activities and 
mechanisms involved in the androgenic actions of the synthetic progestins, 
medroxyprogesterone acetate (MPA) and norethindrone acetate (NET-A). These 
compounds and/or their metabolites exert contraceptive actions and have been shown to 
interact with a number of the steroid receptors. It is shown that MPA and NET-A both 
elicit partial agonist activity via the androgen receptor. Furthermore, it is demonstrated 
that these progestins have a similar relative binding affinity for the androgen receptor 
when compared to the androgen, mibolerone. NET-A, liice well-characterised androgens, 
induces the ligand-dependent interaction between the NFb- and COOH-terminal domains. 
Contrary to this, MPA not only fails to induce but also represses this androgen-induced 
interaction. However, both MPA and NET-A promote the interaction of steroid receptor 
co-activator 1 (SRC1) with the AF2 domain of the AR. These results thus demonstrate that 
MPA and NET-A exert their androgenic actions by different mechanisms.
Introduction
In many parts of the world, long-acting contraceptives constitute an important 
option in family planning services. For more than 20 years two long-acting injectable 
contraceptives, containing only a synthetic progestin, have been in clinical use. These are
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depot-medroxyprogesterone acetate (DMPA) and norethindrone enanthate (NET-EN; 
frequently referred to as norethisterone enantate) (Garza-Flores et al., 1991). DMPA is a 
150 mg aqueous suspension administered every three months, whereas NET-EN is a 200 
mg oily suspension administered every two months. Both formulations are adminstered as 
intramuscular injections. There are apparent differences with respect to the stability and 
metabolism of the two contraceptive agents. Medroxyprogesterone acetate (MPA) is 
relatively stable and is itself the active contiaceptive compound. On the other hand, NET- 
EN is rapidly hydrolysed to norethindrone (NET) and its metabolites (Stanczyk and Roy, 
1990) many of which, together with NET, exert the contraceptive action. Contraceptive 
doses of DMPA and NET-EN result in serum concentrations of about 2.6 nM of MPA 
(Mishell, 1996) and 1 . 5 - 5 9  nM of NET (Fotherby et al., 1983). These agents are, 
however, also used in therapy for the treatment of cancer or as replacement hormones, and 
are then administered at much higher doses. The contraceptive mechanism of MPA action 
involves the prevention of ovulation by abolishing peak mid-cycle gonadotropin levels 
(reviewed by Mishell, 1996 and Kaunitz, 1998). NET-EN has also been shown to block 
ovulation (Bhowmik and Mukherjea, 1988). However, the primary contraceptive action of 
NET-EN involves changing the content of cervical mucous to a progestogenic phase that 
prevents sperm penetration (Bhowmik and Mukherjea, 1987). The mechanisms of action 
of MPA and NET have been assumed to be elicited by their ability to interact with the 
progesterone receptor (PR), as both compounds are progestins. However, it has been 
demonstrated that MPA has high affinity and is an agonist for the PR, glucocorticoid 
receptor (GR), and androgen receptor (AR) (Teulings et al., 1980; Bentel et al., 1999; 
Kempainnen et al., 1999; Bojar et al., 1979; Bergink et al., 1983; Feil and Bardin, 1979). 
Such activity for NET has only been demonstrated for the PR and AR (Decker et al., 
2000).
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The AR, GR and PR, together with the estrogen and mineralocorticoid receptors, 
constitute the steroid receptor family. They are ligand-dependent transcription factors that 
display a high level of similarity with regards to their structure and mechanism of action. 
The structural arrangement of the different domains of these receptors involves the highly 
variable NH2-terminal domain (NTD), followed by the highly conserved and centrally 
located DNA-binding domain (DBD), which directly interacts with the DNA response 
elements. The DBD is linked to the COOH-terminal (C terminal) domain by the hinge 
region. The C-terminal domain contains the ligand binding domain (LBD) to which the 
ligand, a steroid hormone, binds. Furthermore, these receptors also possess transcriptional 
activation functions located in the NTD (AF1 domain) and the LBD (AF2 domain). Once 
bound by steroid these, mostly cytoplasmic, receptors are activated and translocate to the 
nucleus where they bind to specific DNA sequences, called response elements, and 
subsequently regulate gene expression (Evans. 1988; Beato, 1989).
For the AR an interaction between the NTD and LBD (N/C-interaction), that is 
dependent on ligand binding, has been demonstrated (Langley et al., 1995; Doesburg et 
al., 1997), and found to be essential for optimal AR function (Ikonen et al., 1997). Studies 
to reveal the subdomains involved in this interaction implicate the AF2 domain in the 
LBD (Berrevoets et al., 1998; Fie et al., 1999), and two LQ L L-like motifs in the NTD 
(He et al., 2000) as being important. These LA^'X-like motifs form, in part, the interface 
for the interaction of the NTD with the AF2 domain. Functional interactions between the 
transcriptional activation domains of the AR and the 160-kDa (pi 60) nuclear receptor co­
activators have also been demonstrated (Alen et al., 1999). These co-activators have 
distinct regions that interact with the AF1 and AF2 domains of the AR. It has been
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demonstrated that the p i 60 co-activator, steroid receptor co-activator 1 (SCR1), directly 
interacts with the NTD (AF1 domain) of the AR via a glutamine-rich region that is 
conserved amongst the members of this family of co-activators (Bevan et al., 1999). These 
co-activators also interact, in a ligand-dependent manner, with the LBD (AF2 domain) of 
steroid receptors via three highly conserved a-helical LXXLL motifs that are centrally 
located in the nuclear receptor interacting region (Heery et al., 1997; Voegel et al., 1998).
MPA and NET have both been shown to possess androgenic activity. However, 
little research has been done to directly compare their relative activities and the precise 
mechanisms involved. Furthermore, both contraceptive agents have a number of contra­
indications. Since these compounds are not specific for the PR, but also bind to other 
steroid receptors, they may exert side-effects via any of these receptors. This highlights the 
importance of understanding the interactions of these compounds with steroid receptors. In 
the present study we focus on the AR and compare the relative androgenic properties of 
MPA and norethindrone acetate (NET-A) with those or androgens (refer to figure 1 for 
structures). NET-A was used in these studies since, similarly to NET-EN, NET-A is 
rapidly hydrolysed to the parent compound, NET, and its metabolites (Stanczyk and Roy, 
1990). We investigate the effects that these compounds have on binding to the AR, 
transcriptional activation via the AR, the N/C-interaction of the AR as well as the 
interaction of SRC1 with the AF2 domain of the AR, to directly compare the 
androgenicity of MPA and NET-A.
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Figure 1: The chem ical structures o f natural and synthetic androgens and progestins.
The (A) natural androgen, testosterone (T); (B) synthetic androgen, mibolerone\ (C) natural 
progestin, progesterone-, (D) synthetic progestin, medroxyprogesterone acetate (MPA)', and (E) 
synthetic progestin, norethindrone acetate (NET-A).
Stellenbosch University http://scholar.sun.ac.za/
92
Materials and methods 
Plasmids
The plasmid pTAT-GRE-Elb-luc, was used as a reporter and is driven by the E lb  
promoter that contains two copies of the rat TAT-GRE (a gift from G. Jenster). A plasmid 
expressing the human androgen receptor, pSVARo (Brinkmann et al., 1989), was used. 
The hAR DBD-LBD expression vector, pSG5-hAR(DBD-LBD), as well as the hAR 
NTD-VP16 fusion protein expression vector, pSNATCH-II(hAR-NTD), were previously 
described in (Alen et al., 1999). The expression vector for SRC1, pSG5-SRCl, was 
obtained from M.G. Parker.
Preparation of test compounds
5a-androstan-17p-ol-3-one (dihydrotestosterone; DHT), 6a-methyl-17a-hydroxy- 
progesterone acetate (medroxyprogesterone acetate; MPA), and 17a-ethynyl-19- 
nortestosterone 17p-acetate (norethindrone acetate; NET-A) were obtained from Sigma- 
Aldrich. Mibolerone was obtained from Dupont, NEN. All test compounds were dissolved 
in ethanol. These compounds were then added to the culturing medium such that the final 
concentration of ethanol did not exceed 0.1%. Control mcubations (no test compounds) 
were performed in the presence of only 0 .1% ethanol.
Transfections
Monkey kidney COS-7 cells (a gift from M.G. Parker) were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% (v/v) fetal calf 
serum (Gibco-BRL Life Technologies), penicillin (100 IU/ml) and streptomycin (100 
lU/ml) in a humidified 5% CO2 incubator. For transfection experiments, cells were seeded
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into 96-well tissue culture plates (Nunc) at 104 cells per well and grown in phenol red free 
DMEM supplemented with 5% (v/v) dextran-coated charcoal-stripped serum. On day 2, 
cells were transfected with FuGENE6  transfection reagent (Roche Molecular 
Biochemicals) in accordance with the manufacturer’s instructions. The basic DNA mixture 
for transfections consisted of (per well): 1 0 0  ng of the appropriate luciferase reporter 
constructs, 10  ng of the appropriate expression vectors for either a human steroid receptor 
or relevant fusion proteins, and 10  ng of the cytomegalovirus (CMV)-driven-(3- 
galactosidase expression vector (Stratagene). On day 3, media were replaced, either with 
or without the addition of the appropriate hormones. On day 4, cells were harvested by 
incubation for 10 min in 25 pi of 1 X passive lysis buffer (Promega). A 2.5 pi aliquot of 
cellular extract was used for the quantification of luciferase in a Luminoskan Ascent 
Luminometer with luciferase assay reagent (Promega) in accordance with the 
manufacturer’s instructions. The p-galactosidase activity in a 2.5 pi aliquot of extract from 
each sample was measured with the P-galactosidase chenr luminescent reporter gene assay 
system (Tropix Inc.). P-Galactosidase readings were used to assess transfection efficiency 
and normalise luciferase readings. The reported values are averages of at least three 
independent experiments, with each condition performed in triplicate.
Whole Cell Binding Assays
COS-7 cells were maintained as above and seeded into 24-well tissue culture plates 
(Nunc) at 5 x 104 cells per well and grown in phenol red h'ee DMEM supplemented with 
dextran-coated charcoal-stripped serum (5%). On day 2, cells were transfected (FuGENE6  
transfection reagent) with 0.75 pg pSVARo expression vector and 0.15 pg pCMV-p- 
galactosidase expression vector. On day 4, the cells were incubated for 90 min at 37°C 
with 1 nM [’HJmibolerone (Dupont, NEN) in the absence and presence of an increasing
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concentration of unlabelled mibolerone, MPA, or NET-A. Working on ice, cells were 
washed three times with ice-cold 1 X PBS for 15 min. Cells were then lysed with 200 pi 
1 X passive lysis buffer. Lysates were briefly centrifuged to remove cellular debris and 
total binding was determined for 150 pi of cellinar extract by scintillation counting. Non­
specific binding was determined as the counts obtained when cells were incubated with 1 
nM [’Hjmibolerone in the presence of 10 000 X unlabelled mibolerone (10 pM). Specific 
bound mibolerone was calculated as the difference between total and non-specific binding. 
(3-Galactosidase activity of 5 pi cellular extract was determined as described above. The 
reported values are averages of two independent assays, with each condition performed in 
triplicate. Data was plotted as the percentage |3II]mibolerone specifically bound, after 
normalizing with p-galactosidase activity, where 1 0 0 % specific binding was taken as non­
specific binding subtracted from total binding.
Data manipulation and statistical analysis
The Graph Pad Prism® programme was used for data manipulations, graphical 
representations, and statistical analysis. One-way ANOVA and Bonferroni test (as post­
test) were used for statistical analysis. In graphical representations, bars that are 
significantly different (p<0.05) according to the statistical test are labelled with different 
letters of the alphabet. Non-linear regression and one site competition were used in whole 
cell binding assays. For all experiments, unless otherwise indicated, the error bars 
represent the SEM of three independent experiments, where each point was performed in 
triplicate.
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Results
M PA and NET-A have a similar relative binding affinity for the AR.
In a competitive whole cell binding assay where COS-7 cells were transiently 
transfected with a full-length hAR expression vector, we .show that both MPA and NET-A 
are able to compete with [3H]mibolerone for binding to the hAR (figure 2A). The curves 
for both MPA and NET-A are consistent with competitive binding to the same site as 
mibolerone. These homologous/heterologous displacement curves were analysed and the 
EC50 values for each compound were determined and are reported in figure 2B. The 
results show that MPA and NET-A bind to the AR with about a 10- and 40-fold lower 
relative affinity than mibolerone, respectively. Although it appears that MPA binds with a 
greater relative affinity than NET-A, this diflerence is not statistically significant. It is 
therefore concluded that MPA and NET-A have similar, but lower relative affinities than 
mibolerone for the AR.
MPA and NET-A display similar androgen agonist activity.
To directly compare the androgenic properties of MPA and NET-A, COS-7 cells 
were transiently transfected with a GRE-driven veporter construct (containing two copies 
of the rat TAT GRE) and a human a’ldroger. receptor (hAR) expression vector. 
Subsequently the cells were exposed to increasing amounts of DHT, MPA or NET-A. 
Figure 3 clearly indicates that MPA and NET-A have similar and relatively strong agonist 
potency for the AR. Even at lO' 13 M, both MPA and NET-A show apparent agonist action. 
Furthermore, the similar levels of maximal induction displayed by MPA and NET-A also 
indicates that these compounds have a similar efficacy for agonist activity via the hAR. 
MPA and NET-A appear to have about a 50% lower efficacy compared to that of DHT.
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Log [Cold Com petitor] (M)
B Binding curve data Differences in log EC50-values
Competitor EC50 (M) (+/-)SEM Competitors Significance
Mibolerone 6.53x1 O'10 1.0 Mib vs MPA *
MPA 6.79x1 O'9 1.1 Mib vs NET-A **
NET-A 2.73x10-8 1.6 MPA vs NET-A ns
Figure 2: MPA and NET-A both com pete with |JH]mibolerone for binding to the human 
androgen receptor.
A. COS-7 cells were transiently transfected with the pSVARo and pCMV-P-galactosidase 
expression vectors. Forty-eight hours later they were incubated with 1 nM [3H]mibolerone in the 
absence and presence o f  increasing concentrations o f  either mibolerone ( ■ ) ,  MPA (-*•) or NET-A  
(▼ ) for 90 minutes. Competition for binding is illustrated by the percent o f  [3H]mibolerone 
specifically bound to the hAR (normalised to P-galactosidase expression). Results are averages o f  
three independent experiments with each condition in triplicate (±SEM). B. Analysis o f  data to 
obtain EC50-values for binding curves, as well as the coiresponding SEM-values and statistical 
significance. P-values < 0.5 and 0.01 are represented oy * and ** respectively, and ‘n s’ stands for 
no significant difference.
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750
Log [DHT] (M) - -11 -10 -9 -8 -7 -6 - 5 .........................................................................................................................................................................
Log [MPA] ( M ) .............................. - - - - 1 6 - 1 5 - 1 4 - 1 3 - 1 2 - 1 1 - 1 0  -9 -8 -7 -6 - 5 .......................................................................................
Log [NET-A] ( M ) ................................................................................................................................................1 6 - 1 5 - 1 4 - 1 3 - 1 2 - 1 1 - 1 0 - 9  -8 -7 -6 -5
Figure 3: MPA and NET-A display sim ilar androgen agonist activity.
COS-7 cells were transiently transfected with the pTAT-GRE-Elb-luc reporter, the pSVARo and 
pCMV-P-galactosidase expression vectors. Subsequently, the cells were exposed to no hormone, 
DHT (hatched bars), MPA (solid black bars' or NET-A (grey bars) at various concentrations for 24 
hours. Induction is expressed in relative light units (rlu). Results are averages o f  three independent 
experiments with each condition in triplicate (±SEM).
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NET-A, but not MPA, induces the ligand-dependent interaction between the amino- 
and carboxyl-terminals of the androgen receptor.
The functional, in vivo, androgen-dependent interaction between the NTD and 
LBD of the AR has previously been demonstrated in both yeast and mammalian cells 
(Langley et al., 1995; Doesburg et al., 1997). Here we used a mammalian two-hybrid 
assay to investigate the potential of MPA and NFT-A to induce the N/C-interaction of the 
hAR. In transient transfection assays, COS-7 cells were cotransfected with a GRE-driven 
reporter construct; an expression vector encoding the DBD and LBD of the hAR; as well 
as an expression vector encoding the NTD of the hAR fused to a VP 16 activation domain. 
In figure 4A we show that, unlike DHT (bars 1 to 4), MPA is not able to induce the N/C- 
interaction of the AR (bars 5 to 8 ). Furthermore, we demonstrate that with increasing 
concentrations, MPA is able to repress the DHT-induced interaction (bars 9 to 12).
In figure 4B, in contrast to MPA, we show that NET-A (bars 5 to 8 ) has the ability 
to induce the N/C-interaction of the AR, similarly to DHT (bars 1 to 4). When the cells are 
incubated with both androgen and NET-A, this level of induction is maintained (bars 9 to 
12). Therefore, when comparing the two contraceptive compounds it would appear that 
NET-A displays behaviour that is more characteristic of classical strong androgen agonists 
(Kemppainnen et al., 1999).
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Figure 4: In contrast to DHT and NET-A, MPA does not induce the ligand-dependent N/C- 
interaction of the hAR.
COS-7 cells were transiently transfected with the pTAT-GRE-Elb-luc reporter, the pSG5- 
hAR(DBD-LBD), the pSNATCH-II(hAR-NTD) aid  th~ pCMV-(3-galactosidase expression vectors. 
Subsequently, the cells were exposed to the indicated test compounds, (A) MPA and (B) NET-A, 
for 24 hours. Induction is expressed in relative light units (rlu). Results are averages o f  three 
independent experiments with each condition in triplicate (±SEM).
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MPA and NET-A both facilitate the ligand-dependent recruitment of the co­
activator, SRC1, to the AF2 domain.
To further characterise the mechanism by which MPA and NET-A elicit their 
androgenic actions, transient transfections were performed to determine the effect o f each 
compound on the recruitment of the coacti '/aior, SRC1, to the AF2 domain of the hAR. 
The ligand-dependent interaction between SRC1 and the AR LBD has previously been 
demonstrated in a mammalian (Alen et al., 1999) as well as a yeast (Bevan et al., 1999) 
system. In these experiments, the mammalian COS-7 cell-line was cotransfected with the 
GRE-driven reporter construct, the vector expressing the DBD-LBD of the hAR, and a 
SRC1 expression vector. In figure 5A we show that MPA, similar to DHT, facilitates 
recruitment of SRC1 to the LBD of the hAR. Since it is shown in figure 2 that MPA binds 
to the AR, the result in figure 5A together with that of figure 2 implies that MPA binds to 
the LBD and thereby induces the conformational changes in this domain that allow SRC1 
to interact with the AF2 domain of the hAR (bars 5 to 8 ), with a similar efficiency to that 
of DHT (bars 1 to 4). When the cells were incubated with both DHT and MPA (bars 9 to 
12), the level of induction was maintained. Similarly, figure 5B indicates that NET-A is 
also able to induce the changes necessary to allow SRC1 to interact with the AF2 domain 
(lanes 5 to 8 ), with a similar efficiency to that of DHT (bars 1 to 4). This level of induction 
was maintained when the cells were incubated with both DHT and NET-A (bars 9 to 12).
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A 150
1 2 3 4 5 6 7 8 9 10 11 12
Log [DHT] (M) - -9 -8 - 7 .......................... 7 - 7  -7 -7
Log [MPA] ( M ) .......................... 9 -8 -7 -6 -9 -8 -7 -6
b
1 2 3 4 5 6 7 8 9 10 11 12
Log [DHT] (M) - -9 -8 - 7 .......................... 7 - 7  -7 -7
Log [Net] ( M ) .......................... 9 -8 -7 -6 -9 -8 -7 -6
Figure 5: Similarly to DHT, MPA and NET-A are both able to induce the ligand-dependent 
interaction of the co-activator, SRC1, with the AF2 domain.
COS-7 cells were transiently transfected with the pTAT-GRE-Elb-luc reporter, the pSG5- 
hAR(DBD-LBD), the pSG5-SRCl and the pCMV-p-galactosidase expression vectors. 
Subsequently, the cells were exposed to the indicated test compounds, (A) MPA or (B) NET-A, for 
24 hours. Induction is expressed in relative light units (rlu). Results are averages o f  three 
independent experiments with each condition in triplicate (±SEM).
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Discussion
The whole cell binding assays of the present study reveal that both MPA and NET- 
A compete for binding to the hAR with a similar, significantly lower, affinity than that of 
mibolerone (figure 2A). The trend observed in figure 2A indicates that MPA may have a 
slightly greater affinity for the hAR than NET-A. However, figure 2B shows that, in the 
context of this series of experiments, there is no significant difference in the relative 
binding affinities of MPA and NET-A for the hAR. This result is consistent with a 
previous report where it appears that, in intact MCF-7 cells, NET and MPA bind with a 
similar relative affinity to the endogenously expressed AR (Bergink et al., 1983 and 
references therein). The data used in this report is, however, obtained from separate 
studies. The result reported in the present study may therefore better reflect the relative 
affinities of these compounds, as a direct comparison between the two compounds was 
made. The present study confirms that MPA and NET-A have similar relative binding 
affinities for the hAR.
Our results show for the first time, by direct comparison, that MPA and NET-A 
have similar androgenic activity (figure 3). Kemppainen et al., 1999, showed that 100-fold 
more MPA is required to achieve the same agonist activity as DHT, mibolerone and 
R1881. This AR agonist activity was determined in CV-1 cells transiently transfected with 
a mouse mammary tumor virus (MMTV)-luciferase reporter and full-length hAR 
expression vectors. In a separate study, the relative agonistic activity of NET for the AR 
was found to be only about 1% of that of DHT (Deckers et al., 2000). In these studies 
CHO cells stably transfected with the MMTV-luciferase reporter and hAR expression 
vectors were used. In these two aforementioned studies, MPA and NET are both required
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at concentrations 100-fold greater than DHT to achieve the same agonist activity as this 
androgen, and as a consequence MPA is described as a weak AR agonist whereas NET is 
said to have low androgenic activity. In the present study we demonstrate that although 
MPA and NET-A exhibit similar and potent AR agonist activity, they both have a lower 
efficacy of about 50% of that of DHT. They can thus be described as partial AR agonists 
in the context of the present study (figure 3). Although both MPA and NET-A have a 
lower efficacy in comparison to DHT, the efficacy of these compounds in our study is 
much higher than that reported in the studies mentioned above. The discrepancies between 
the results, reported in the present as compared to previous studies, could be attributed to 
the different systems in which the agonist activities were measured. If this is the case, then 
contributing factors could be the cell-line used and/or the sequence or context of the 
hormone response element used in the reporter construct.
Amongst the factors contributing to the potency of a ligand are its affinity for the 
receptor, as well as its influences on dissociation of heat-shock proteins, nuclear 
translocation, receptor conformation and stabilisation, the recruitment of essential co­
factors and transcription machinery, as well as DNA binding and rate of ligand 
dissociation. Having addressed the issue of ligand binding the next step was to study the 
influence of MPA and NET-A on some of the other parameters. Therefore, the issue of 
receptor conformation and stabilisation was investigated. In this regard we focused on the 
characteristic N/C-interaction of the hAR. It was found that MPA, although it can compete 
for binding to and is an agonist for the AR, does not induce the N/C-interaction (figure 
4A). These results are consistent with those previously reported by Kemppainen et al., 
1999. The ability of a compound to bind to the AR but not induce the N/C-interaction has 
been reported for the anti-androgens hydroxyflutamide (Langley et al., 1995; Kemppainen
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et al., 1999) and cyproterone acetate (Kemppainen et al., 1999). These results suggest that 
the conformation of the AR resulting from the N/C-interaction is not imperative to render 
the receptor transcriptionally active, since MPA stili has the ability to activate an 
androgen-responsive reporter. In contrast, NET-A, which is demonstrated to be an agonist 
that competes for binding to the AR, was indeed able to induce the N/C-interaction (figure 
4B). An explanation for this difference could be the fact that MPA is a 21-carbon series 
steroid and therefore a true progestin, whereas NET-A is a 19-carbon series steroid and 
therefore structurally more closely related to the androgens. This difference in the 
structures could therefore account for the more typical androgenic profile of NET-A.
Lastly, we determined whether or not these two compounds in any way influenced 
the ligand-dependent recruitment of co-activator proteins. Here we studied the interaction 
between the AF2 domain of the AR and the p i60 co-activator protein, SRC1. Both MPA 
and NET-A were able to induce the ligand-dependent interaction between SRC1 and the 
AF2 domain with similar efficacy to androgen. The structural relationship of the test 
compound to androgens does not appear to influence this ligand-dependent interaction.
The inability of MPA to induce the ligand-dependent N/C-interaction suggests that 
MPA and NET-A activate the AR by different mechanisms. Crystal structure analysis of 
the retinoic acid receptor-y (Renaud et al., 1995), thyroid hormone receptor (Wagner et al., 
1995) and estrogen receptor (Brzozowski et al., 1997) show that ligand binding causes 
helix 12 of the C-terminal domain to undergo a conformational change that closes the 
ligand binding pocket. This change in conformation allows the receptor to ‘hold’ the 
bound ligand. Such closure of the ligand binding pocket by helix 12 has also been 
proposed for the AR. For the AR closure of the pocket by helix 12 is thought to slow the
104
Stellenbosch University http://scholar.sun.ac.za/
rate of ligand dissociation (Zhou et al., 1995). Furthermore, this change in conformation 
forms the interface for the N/C-interaction, in that the AF2 domain is activated (Zhou et 
al., 1995; Kemppainen et al., 1992). Ligand-dependent activation of the AF2 domain is 
also required for the recruitment of co-activators to this domain (Alen et al., 1999). 
Therefore, although MPA does not induce the N/C-interaction, the ability of MPA to 
induce recruitment of SRC1 to the AF2 domain implies that this domain is still activated 
by the closure of the ligand-binding pocket by helix 12.
Our finding that NET-A shows similar efficacy to MPA in inducing transcription 
via the AR, but has a different effect on the N/C-interaction, suggests that the effect that a 
compound has on the N/C-interaction is not the main determinant for agonist activity. 
Other factors such as the dissociation of heat-shock proteins, nuclear translocation, DNA 
binding affinity and rate of ligand dissociation may also play a role. The results presented 
are not consistent with the finding that the degree of agonist potency at low physiological 
concentrations parallels the ability of a compound to induce the N/C-interaction 
(Kemppainen et al., 1999). The results in this study clearlv show MPA to be a potent AR 
agonist, at low concentrations, even though it does not induce the N/C-interaction.
At present women are exposed to an array of contraceptive choices. Elucidating the 
mechanisms by which contraceptive agents exert their effects, will provide women and 
their clinicians with more information to facilitate the selection of method of 
contraception. These insights into mechanisms of action could also facilitate improved 
drug design for contraceptive agents and be helpful in unravelling molecular mechanisms 
by which these compounds exert their side effects. This need to better our understanding 
of these mechanisms is extended to the concern that breast-fed infants will be exposed to
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significant quantities of progestins, if the mother is receiving contraceptive doses of the 
intramuscularly administered progestins (Fotherby et al., 1983). Evidence that neo-natal 
exposure to progestin via milk can exert an effect on the subsequent generation has been 
provided in rat experiments (Holzhausen et al., 1984). In this study female pups were 
exposed to progestins via maternal milk. When they reached adulthood the effects o f these 
progestins on cyclicity in these rats were measured. It was found that MPA, but not NET- 
EN, significantly reduced the pro-oestrus luteinizing hormone (LH) peak as well as the 
total amount of LH secreted during pro-oestrus, and that neither MPA nor NET-EN had an 
affect on pro-oestrus progesterone secretion.
The progestins used in this study have clinical applications other than being used 
as female contraceptives. Firstly, both MPA and NET are used in the treatment of breast 
cancer, and have a number of other therapeutic uses, at doses that are higher than those 
used for contraception. Secondly, NET-EN is going through clinical trials to be used in 
combination with the long-acting testosterone ester, testosterone undecanoate (TU) as a 
male contraceptive (Kamischke et al., 2000a; 2000b; 2002). These applications once again 
highlight the importance of defining the mechanisms of action by which these compounds 
function and potentially exert their side effects. More importantly, there is a need to 
directly compare the mechanisms by which these compounds act. The results of this study 
emphasise this point as it is demonstrated that compounds used for the same applications 
can have different effects at the molecular level. The different effects that MPA and NET- 
A have on the ligand-dependent N/C-interaction of the AR are just a single example, the 
physiological significance of which remains unknown. However, this ability o f different 
compounds to exert similar effects via different mechanisms raises the concern that such
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compounds could then also exhibit very different effects via steroid receptors in some 
target tissues, depending on the promoter and repertoire of co-factors.
Although all steroid hormones are structurally similar, relatively minor differences 
can cause profound alterations in their biochemical activity. Taken together our results 
provide evidence for such differences in activity at the molecular level, once again 
emphasising the importance of defining the mechanisms of action of each of these 
compounds.
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3.2 Comments and suggestions
One of the main concerns about the data, presented in the current version of 
the manuscript, is that the whole cell binding assay was performed using mibolerone 
as reference androgen, whereas the rest of the assays were performed using DHT as 
reference androgen. It is well established that the relative binding affinities of these 
two androgens for the AR differ. Mibolerone has a greater affinity than DHT for the 
AR. This makes it difficult to directly compare and correlate the data obtained from 
the different assays performed in the present study. It is thus proposed that at least two 
of the assays be repeated. Firstly, the whole cell binding assay will be repeated. Once 
again | ’HJmibolerone will be used and homologous displacement by mibolerone as 
well as heterologous displacement by DHT, MPA and NET-A, will be performed. 
Secondly, the transactivation assay will be repeated and dose response curves 
obtained for mibolerone, DHT, MPA and NET-A.
In repeating the whole cell binding assay, a few other parameters could be 
optimised to yield data from which more information can be obtained. In the assay
■3
presented in the manuscript, 1 nM [HJmibolerone was used. The EC50-value 
obtained from the homologous displacement curve of mibolerone is 0.653 nM (figure 
2B). The EC50-value of mibolerone is lower than the concentration of 
[■’HJmibolerone used and therefore it is not possible to obtain an accurate Kd for 
mibolerone from this data. Thus, when repeating this series of experiments, lower 
concentrations of [3H]mibolerone (e.g. 0.1 nM) will be tested, to obtain an EC50- 
value about 2 to 10 times higher than the concentration of [ H] mibolerone used, in 
order to calculate an accurate Kd for mibolerone. Once the Kd for mibolerone has
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been established in this system, the relative Ki values for DHT, MPA and NET-A can 
also be determined, which will better reflect the relative binding affinities of these 
compounds for the AR.
In repeating the transactivation assay, again there are some parameters that 
could be altered to obtain more information from the results. Together with including 
incubation with mibolerone, it is further suggested that incubations with additional 
concentrations for DHT be included. It is therefore suggested that for all the 
compounds, DHT, mibolerone, MPA and NET-A, a concentration range of at least 
10‘16 M to lO0 M be used. For DHT, and possibly also mibolerone, even higher 
concentrations may be necessary to determine the true maximum of induction. The 
current data may not necessarily reflect this for DHT, because there is only one 
concentration (10° M) at which this maximum is attained, and at least two 
consecutive concentration points that are not significantly different from one another 
are required. The result obtained from this suggested experiment would therefore also 
allow a better comparison of the relative efficacies of the different compounds. 
Furthermore, the new data could also be plotted as dose-response curves for which the 
EC50-values could be determined. This would allow a more accurate quantification of 
the relative potencies of the compounds. Taken together, repeating this experiment 
will most likely still show MPA and NET-A to be partial AR agonists, but this 
interpretation will be based on better statistical evidence
In the present study it is suggested that both MPA and NET-A facilitate the 
recruitment o f SRC1 to the AF2 domain of the hAR in a mammalian two hybrid 
assay. However, the assay can not exclude the possibility that another co-activator
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besides SRC1 is facilitating transcription and therefore the data do not show 
conclusively that there is a direct interaction between the AF2 domain and SRC1. To 
definitively show direct interaction a more direct assay such as GST pull-down assays 
could be performed.
Lastly, all of the assays used were based on the overexpression of the AR in 
the COS-7 cell-line and thus do not reflect the effects of the test compounds on 
physiological AR. It is therefore also proposed that the actions of MPA and NET-A 
via endogenously expressed AR be tested. Two further experiments in this regard are 
suggested. The ability of MPA and NET-A to activate transcription of an androgen- 
specific responsive (ARE-) reporter construct transfected into a cell-line that 
expresses endogenous AR could be studied. Finally, the effect of MPA and NET-A on 
the expression o f androgen-dependent, endogenously expressed protein (i.e. the PSA 
proteins in the LNCaP cell-line) could also bCT investigated. In both o f these 
experiments additional incubations with MPA/NET-A in the presence of an AR- 
specific antagonist (e.g. hydroxyflutamide) will be included. This will determine 
whether the AR is involved in MPA-/NET-A- induced transactivation of the ARE- 
reporter as well as in the expression of PSA.
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Chapter 4
Discussion and Concluding Remarks
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4.1 Summary and discussion of the results presented in this thesis
The results of the two studies presented in this thesis have been summarised in 
Table I. This table will be referred to extensively in this discussion, to highlight the 
issues raised as well as the insights gained from these studies.
The anti-androgenic actions of CpdA are summarised in Table I. Although 
CpdA does not activate transcription via the AR it can, at 10 |U.M, repress R 1881- 
induced activation of both non-specific and specific androgen response elements 
(AREs) (Chapter 2; figure 2). In contrast to CpdA, MPA and NET-A display partial 
androgen receptor agonist activity in transactivation assays (Chapter 3; figure 3). The 
whole cell binding assays revealed that CpdA does not compete (Chapter 2; figure 4), 
whereas MPA and NET-A are able :o compete (Chapter 3; figure 2) with 
[’HJmibolerone for binding to the AR. These results are consistent with the actions of 
CpdA, MPA and NET-A observed in the transactivation assays with respect to agonist 
activity. The inability of CpdA to compete for binding was unexpected, since anti­
androgens normally compete with androgens for binding. In this respect, CpdA 
appears to be unique in its mechanism of eliciting its anti-androgenic actions. 
However, this ability of a compound to modify the action of a steroid receptor without 
directly binding to the receptor is not unique, since it has been demonstrated that 
ursodeoxycholic acid can activate the GR into a DNA binding species without direct 
binding to the GR (Tanaka et al., 1996).
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Table 1: Summary of Results
Assay
Test compound
CpdA MPA NET-A
Steroidal or non­
steroidal compound Non-steroidal Steroidal Steroidal
Transactivation of GRE- 
responsive reporter via 
the AR
No Yes Yes
Repression of androgen- 
induced activation of 
GRE-responsive reporter
Yes ND ND
Repression of androgen- 
induced activation of 
androgen-specific 
responsive reporter
Yes ND ND
Repression of ligand- 
induced activation via 
other SRs
Yes, the PR ND ND
Competitive binding for 
the AR No Yes Yes
Induction of N/C- 
interaction No No Yes
Repression of ligand- 
induced induction of 
N/C-interaction
Yes Yes No
Induction of SRC1 
recruitment to AF2 
domain
No Yes Yes
Repression of ligand 
induced recruitment of 
SRC1 to AF2 domain
Yes, slightly ND ND
Effect on SRC1 
interaction with the NTD No ND ND
Effect on constitutive 
activity of NTD No ND ND
Where n d  stands for 'not determined1.
To further define the mechanism(s) by which these compounds exert their 
effects, their interactions with the LBD of the AR were investigated. Here two assays 
that rely on the binding of the androgen to the LBD with the subsequent activation of 
the AF2 domain were used.
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The first assay measured the N/C-interaction. Here it was shown that CpdA 
itself is unable to induce the ligand-dependent N/C-interaction (Chapter 2; figure 5A) 
and that, similarly to other anti-androgenic compounds (Langley et al., 1995; 
Kemppainen et al., 1999), CpdA represses the DHT-induced interaction of these 
domains. An intriguing result was observed when this assay was performed for the 
two progestins. Although MPA displayed androgenic actions in the transactivation 
experiments, it was unable to induce the N/C-interaction. DHT and NET-A, on the 
other hand, were able to induce this interaction, as was expected considering they 
both exert androgenic effects in the transactivation experiments. More surprising was 
the fact that MPA repressed the DHT-induoed N/C-interaction similarly to anti- 
androgenic compounds such as hydrox\ fiutamide, cyproterone acetate and CpdA. 
These results imply that MPA activates the AR by a mechanism that differs from 
conventional agonist and NET-A action. Furthermore, the results suggest that MPA, 
but not NET-A, displays anti-androgen activity.
CpdA did not displace agonist from the AR nor did it prevent agonist binding 
to the AR, yet it was able to inhibit transactivation as well as the N/C-interaction 
induced by the agonist. MPA, on the other hand, could displace agonist from the AR 
and could transactivate via the AR, and yet, like CpdA, did not induce the N/C- 
interaction and also inhibited agonist induced N/C-interaction. It was therefore 
postulated that the lack of N/C-interaction and inhibition of agonist-induced N/C- 
interaction by CpdA and MPA might extend to an additional feature of the activation 
of the LBD, namely recruitment of co-activator profeins to the AF2 domain. A second 
assay was therefore performed, to determine whether closure of the ligand binding 
pocket and thus activation of the AF2 domain takes place in the presence of CpdA,
I 18
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MPA and NET-A. Here, the effect of these compounds on the ligand-dependent 
recruitment of SRC 1 to the AF2 domain was studied. It was demonstrated that CpdA 
is capable of repressing this interaction (Chapter 2; figure 5B), although to a lesser 
degree than the repression observed for the N/C-interaction. Because the interaction 
between the AF2 domain and SRC1 is not completely lost, it is unlikely that CpdA 
prevents the structural changes of the LBD that occur as a result of ligand binding. In 
contrast, MPA does not repress this interaction but in fact induces it similarly to NET- 
A and DHT (Chapter 3; figure 5). The regions of the AF2 domain involved in the 
N/C-interaction and the interaction with SRC1 overlap, but are not identical 
(Thompson et al., 2001). Therefore, it is possible that CpdA may interact with or 
modify amino acid residues that are essential for the N/C-interaction and are 
important, but not essential, for the interaction between SRC1 and the AF2 domain. 
MPA, on the other hand, may induce a conformation that compromises amino acid 
residues that are essential for the N/C-interaction but that are not of importance for the 
interaction between SRC1 and the AF2 domain. This suggests that CpdA and MPA 
may exert slightly different effects at the LBD of the AR.
The repressive effect of CpdA on AR activity prompted an additional 
investigation. The potential of CpdA to interact with the NTD of the AR was studied, 
as it is this domain of the AR that has been shown to possess most of the 
transcriptional activity. The effect of CpdA on the ligand-independent interaction 
between the NTD and SRC1 (Chapter 2; figure 5C), as well as its effect on the 
constitutive activity of this domain (Chapter 2; figure 5D), were addressed. It was 
found that CpdA in no way impairs the recruitment of SRC1 to the NTD, and neither 
does it affect the transcriptional activity of the NTD. These results imply that CpdA in
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no way affects the establishment of or interactions of the NTD with the basal 
transcription machinery. These results do not however, exclude the possibility that 
CpdA may interact with region(s) in the NTD that are essential for the N/C- 
interaction but that are not of importance for SRC1 recruitment or the constitutive 
activity of this domain.
Another point to take note of is the fact that CpdA can cyclize to an aziridine 
at physiological pH. Aziridines are highly reactive, unstable alkylating compounds. 
Their more stable precursors are often used clinically in cancer treatment (Calabresi 
and Chabner, 1990). These precursors undergo cyclization to the highly reactive 
aziridine. It is the aziridine ring and its protonated form, that react with nucleophiles 
to form alkylated, ring-opened products (Dermer and Ham, 1969). One possible 
explanation for the anti-androgenic activities of CpdA may be that CpdA is cyclized 
to the aziridine, which could then react with nucleophilic amino acid residues. Such 
modifications to specific amino acid residues could account for the effects that CpdA 
has on, for example, the N/C-interaction. However, if the aziridine is the active 
species then it would be expected that incubations with CpdA would be toxic for the 
various cell-lines used, since aziridines alkylate DNA as well as other biological 
molecules (e.g. proteins) resulting in general cytotoxicity (Calabresi and Chabner, 
1990). CpdA, however, had no effect on SRC1 recruitment to the NTD nor did it 
affect the constitutive activity of this domain. In addition, CpdA had no effect on AR 
or CK18 levels (Chapter 2, figure 6) nor was it generally cytotoxic as evidenced by 
the fact that anti-proliferative effects were seen only with LNCaP cells but not with 
COS-7 cells (Chapter 2, figure II). This indicates that there are no cytotoxic effects
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and therefore suggests that it is CpdA rather than the aziridine that is the active 
species in the transfection experiments performed in this study.
The following conclusions can also be drawn from the data presented in this 
thesis. Firstly, CpdA slightly impairs the recruitment of SRC1 to the AF2 domain but 
has no effect on SRC1 recruitment to the AF1 domain. This result indicates that the 
AF2 domain is more important that the AF1 domain for transactivation via the AR in 
the systems and cell-lines tested in this study. This is contrary to literature reports 
stating that the AF2 domain of the AR displays weak transcriptional activity whereas 
the AF1 domain is the major activating region of the AR (Moilanen et al., 1997). 
Secondly, the different mechanisms of MPA and NET-A action are most likely 
explained by the structural differences between the two compounds. The classical 
mechanism of androgen agonist action displayed by NET-A can be attributed to its 
similarity to testosterone. On the other hai.-d, MPA is more closely related to 
progesterone, which may account for its effects in the N/C-interaction assay, as it has 
previously been shown that progesterone represses the DHT-induced N/C-interaction 
(Kemppainen et al., 1999). Although MPA has a similar effect to CpdA in this assay, 
the mechanisms involved are clearly different as MPA can compete for binding to the 
receptor and transactivate via the receptor. However, the principles may be similar, in 
that in both cases the compound may induce a conformation in the LBD that 
compromises the alignment of amino acid residues of ine AF2 domain. This altered 
arrangement may then hinder the amino acid residues that are essential for the N/C- 
interaction.
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4.2 Implications and future perspectives
4.2.1 Compound A
Anti-androgens are designed for and used in the treatment of a number of 
androgen-dependent diseases. To date, chemical anti-androgen therapy has been 
based on the use of compounds that compete with androgens for binding to the AR 
and as a result inhibit androgen action. In chapter 2 the potential of CpdA to inhibit 
androgen action by a mechanism that does not involve competition for binding is 
described. However, the precise mechanism of action by which CpdA exerts it anti- 
androgenic effects is not yet known. A thorough investigation to further elucidate 
these mechanisms would be of great value. An understanding of CpdA’s actions 
together with knowledge of how other anti-androgenic compounds elicit their effects 
would be extremely useful in aiding the design of therapeutic agents for the treatment 
of diseases such as prostate cancer. Such investigations would also facilitate the 
unravelling of the mechanisms involved in AR action.
With regards to future studies to elucidate the mechanism(s), by which CpdA 
exerts its actions, there are numerous aspects of AR. action that could be investigated. 
Firstly, it is suggested that CpdA may directly interact with a region of the AR. 
resulting in inhibition of the N/C-interaction. Whether CpdA binds to a region of the 
AR other than the LBD could be investigated using custom synthesized [3H]CpdA in 
whole cell binding experiments. Secondly, because it is known that androgen still 
binds the AR in the presence of CpdA, and that CpdA represses the N/C-interaction, 
an investigation of the potential effect of CpdA on me rate at which ligand dissociates 
from the receptor could be performed. The ligand dissociation rate is influenced by
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the N/C-interaction, and has been suggested as a measure of agonist activity 
(Kemppainen et al., 1999).
Furthermore, the influence of CpdA on the conformation of the LBD adopted 
by the ligand-bound receptor protein could be examined. Limited proteolytic 
digestion of in vitro produced AR protein that has been incubated with androgen in 
the absence and presence of CpdA would be a possible strategy. In the presence of 
androgen, the receptor would be expected to generate a protected fragment of about 
29 kDa in size (Kuil et al., 1994). In the presence of both androgen and CpdA, one 
would expect to observe a protected fragment of a different size or no protection at all 
if CpdA alters the androgen-induced conformation of the LBD. However, due the 
unpredictable nature of this assay, as discussed in chapter 1, seeing no effect in the 
presence of CpdA would not necessarily mean chat CpdA has no effect on the 
conformation of the LBD.
Finally, as it is still unclear as to how CpdA exerts its effect, the influence of 
CpdA on other steps in AR functioning could also be investigated. In this respect the 
effects of CpdA on AR dimer formation, DNA binding, dissociation of associated 
proteins (i.e. heat-shock proteins), as well as cellular localisation could be studied.
4.2.2 Medroxyprogesterone acetate and norethindrone acetate
It is assumed that the contraceptive agents, DMPA and NET-EN, exert their 
contraceptive action predominantly via the PR as these compounds are both synthetic 
progestins. However, both of these compounds have been shown to have androgenic 
agonist activity. It was the purpose of this study to define the androgenic properties of 
these two compounds, as it is possible that some of the side-effects observed when 
using these contraceptives could be attributed to their androgenicity. More
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importantly, the aim was to make a direct comparison between the two compounds, as 
to date only some of these aspects have been investigated, and these have not 
involved direct comparisons. The results presented demonstrate how compounds that 
may appear to be structurally similar and possess similar mechanisms of action via 
one SR, can then also exhibit different effects via another SR. An important insight 
into steroid action was therefore highlighted, namely, that different steroid hormones 
have the capacity to exhibit different effects, via different SRs, in various target 
tissues. Therefore, when considering the number of applications of these two 
compounds, it is clear that it is of importance to assess and define their actions under 
various conditions, which in turn could assist clinicians in choosing the most 
appropriate method of treatment.
With regards to future studies to further elucidate the mechanisms of MPA and 
NET-A action via the AR, there are a few elements of AR action that could be 
investigated. Firstly, knowing that both MPA and NET-A bind the AR but that unlike 
NET-A, MPA does not induce the N/C-interaction, it is suggested that the effect of 
these compounds on AR stability as well as the rate at which they dissociate from the 
receptor be investigated. Both ligand dissociation rate and receptor stability are 
influenced by the N/C-interaction, and have been suggested as measures of agonist 
activity (Kemppainen et al., 1999). It would thus bs expected that MPA would 
dissociate from the AR at a quicker rate than NET-A. Since there does not appear to 
be a difference in the potency and efficacy of these two compounds with respect to 
transcriptional activation, it would be interesting if there was indeed a difference in 
their dissociation rates. Secondly, the ability of MPA to repress the androgen-induced 
N/C-interaction confers an anti-androgenic property on MPA. It would therefore be of 
interest to investigate the potential for MPA to repress androgen-induced activation of
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a GRE-responsive reporter. Furthermore, as it is possible that MPA may induce a 
slightly different conformation in the LBD as opposed to NET-A, a comparative study 
of the effects of MPA and NET-A on dimer formation as well as DNA binding 
affinity could be performed. These studies would be appropriate as both stabilization 
of dimer formation and dissociation of hsps involve regions of the LBD.
4.3 Concluding Remarks
Taken together, the experiments presented in this thesis illustrate the 
importance of defining the precise mechanism by which individual compounds exert 
their effects. Although the basic molecular mechanism of steroid hormone action via 
the SRs has been defined, our results demonstrate how both apparently major and 
minor differences in the structures of different compounds can alter the mechanism by 
which a SR acts.
Firstly, with regard to major structural differences we show how non-steroidal 
(CpdA) and steroidal (MPA and NET-A) compounds can affect AR functioning in 
both the same and different ways. Even though CpdA does not compete with 
androgens for binding to the AR, whereas MPA does, it is shown that both of these 
compounds are unable to induce the ligand-dependent N/C-interaction but are able to 
repress the DHT-induced N/C-interaction (refer to Chapter 2; figure 5A and Chapter 
3; figure 4A). Furthermore, CpdA impairs the recruitment of SRC1 to the AF2 
domain whereas MPA has not effect on this interaction (refer to Chapter2; figure 5B 
and Chapter 3; figure 5A). Secondly, by directly comparing the androgenic activities
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of MPA and NET-A, we have shown how minor structural differences between 
steroidal agents can have an effect on their respective mechanisms of action. 
Although both compounds bind the AR and transactivate via the AR, MPA does not 
induce the N/C-interaction whereas NET-A does.
Two important aspects of steroid hormone action were also highlighted. 
Firstly, binding of a compound to the agonist-binding site of the receptor, a basic step 
in AR function, may not be a prerequisite for such a compound to alter the actions of 
the receptor. Secondly, the importance of directly comparing the actions of different 
compounds at the molecular level was demonstrated. This is not only of importance to 
elucidate the mechanisms by which the compounds may act, but also in identifying 
and defining the exact regions of the interacting protein, in this case the receptor 
protein, that are imperative for the optimal functioning of the respective compound.
Finally, combining the knowledge available on AR function (including various 
mechanisms of androgenic and anti-androgenic action) with the results presented 
here, can contribute to an improved understanding of AR functioning. Furthermore, 
such information could also facilitate the development of new anti-androgenic 
compounds for diseases such as prostate cancer, as well as aid the improved design of 
progestins for contraceptive purposes that would be more specific for the PR and 
thereby possibly exert fewer side-effects.
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